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Improving the Biopharmaceutical Properties of Cyclic Opioid 
Peptide Prodrugs 
 
Rebecca A. Nofsinger 
The University of Kansas, 2008 
 
The development of opioid peptides into orally viable therapeutics has been 
limited by their unfavorable drug-like properties.  Poor intestinal permeation and 
enzymatic instability are some of the undesirable qualities exhibited by opioid 
peptides.  To improve the “drugability” of these peptides, we have developed cyclic 
prodrugs of the opioid peptide DADLE (H-Tyr-D-Ala-Gly-Phe-D-Leu-OH).  The 
parent cyclic prodrug CA-DADLE was formed by joining the N- and C-termini of the 
peptide via a coumarinic acid linker (CA).  In the presence of liver microsomes and 
human recombinant cytochrome P450-3A4 (hCYP3A4), CA-DADLE was found to 
be metabolically unstable.  Studies indicated that the instability was a result of 
cytochrome P450 metabolism.  Under oxidative conditions, two main metabolites of 
CA-DADLE were discovered (hydroxylation on Tyr1 and Phe4 residues).  CA-
DADLE was found to be a substrate for efflux transports [i.e., P-glycoprotein (P-gp)], 
which lead to very low cell membrane permeation.  Using this knowledge, analogs of 
CA-DADLE were designed to enhance metabolic stability and possibly improve 
membrane permeation.   
 iii
Cyclic prodrug analogs CA-[Cha4,D-Leu5]-Enk and CA-[Cha4,D-Ala5]-Enk 
were successfully synthesized, investigated for metabolic stability, and evaluated for 
desirable physicochemical properties.  The compounds were found to be 
metabolically unstable in the presence of liver microsomes and showed oxidative 
metabolite formation under these conditions (hydroxylation on Tyr1 and Cha4 
residues).  Surprisingly, the analogs did show stability in the presence of hCYP3A4, 
which is a major metabolic barrier to intestinal absorption.  Molecular surface area, 
cLogP, and solution conformation studies indicated favorable physicochemical 
properties that could potentially lead to increased membrane permeability.   
Finally, cell permeation was examined.  Cyclic prodrug analogs were 
investigated using an in vitro cell culture model as well as an in situ rat intestinal 
perfusion model.  The in situ perfusion model provided the opportunity to 
simultaneously test in vivo cell permeation as well as identify oxidative metabolites  
in vivo.  No oxidative metabolites were detected in the in situ perfusion studies.  In       
in vitro and in vivo models, the analogs were found to be substrates for P-gp, which 
severely limited their membrane permeation.  In conclusion, these molecules would 
need to have increased metabolic stability in the liver and enhanced membrane 
permeation to be orally bioavailable.   
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Chapter 1 
 
Cyclic Peptide Prodrugs of DADLE: A History 
 
 
 
 
 
 
 
 
 
 
 2
1.1 OPIOID PEPTIDES  
Opioid peptides, which were among the first discovered neuropeptides 
discovered,1 have been studied extensively for their possible therapeutic value in 
relieving pain.  The advantage of opioid peptides is that they mimic the effect of 
opiates in the brain (i.e., possessing high affinity for opioid receptors).  Opioid 
receptors are heterogeneous and exist in three main types, classified as µ, δ, and κ.2  
The highest abundance of opioid receptors is in the central nervous system (CNS),3 
but they have also been found in many peripheral tissues.4  By targeting specific 
opioid receptors, opioid peptides can potentially provide therapeutic results with 
reduced side effects.  There are two types of endogenous opioid peptides; they differ 
in the pharmacophoric amino acid sequence of the message domain (at the N-
terminus).5,6  The first class of opioid peptides (enkephalins, endorophins, and 
dynorphins) has a N-terminal sequence of -Tyr-Gly-Gly-Phe-, while the second class 
(endomorphins) has the sequence -Tyr-Pro-Phe/Trp-.  Therapeutic opioid peptides 
and peptiodomimetics are typically modeled after these endogenous systems.   
One of the early leading peptidomimetics to generate interest was a synthetic 
derivative of leucine enkephalin ([Leu5]-Enk) called DADLE.7-9  DADLE is a 
pentapeptide with a modified amino acid sequence of H-Tyr-D-Ala-Gly-Phe-D-Leu-
OH.  In the late 1970s, [Leu5]-Enk’s analgesic effect and specificity toward explicit 
opioid receptors were investiagated.8-12  Wüster et al. and Robson et al. found that 
[Leu5]-Enk and many enkephalin analogs, specifically DADLE, were selective for the 
δ-opioid receptor.9,11  As new analogs were studied, identification of the functional 
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groups and residues important for biological activity was pursued.13,14  Investigations 
for better and more potent analogs continued, and cyclic-enkephalin peptides were 
introduced.  The first cyclic enkephalin peptides [D-Pen2,D/L-Cyc5]-Enk were 
developed by Mosberg.15  They had δ-opioid receptor specificity and biological 
activity and were efficacious in vivo.15  Also from the arena of new cyclic opioid 
peptides, penicillamines ([D-Pen2,D-Pen5]) or DPDPE emerged.  These cyclic 
analogs were highly selective to the δ-opioid receptor and showed a significant 
reduction in side effects.16  Later, the Borchardt and Siahaan laboratories introduced 
cyclic peptide prodrugs of DADLE.17,18  
 
 
1.2 DEVELOPMENT OF CYCLIC PRODRUG STRATEGY 
The development of cyclic opioid peptides with high affinity and selectivity 
toward specific opioid receptors has been ongoing.19-23  Unfortunately, the 
development of these peptides into viable clinical candidates has been limited by their 
lack of enzymatic stability and undesirable physicochemical properties.  These issues 
lead to limited intestinal mucosa permeation and, ultimately, low oral bioavailability.  
The cyclic prodrug strategy was employed to create cyclic peptide prodrugs that 
would overcome these problems while maintaining biological activity.  The strategy 
has three main objectives: (i) to enhance membrane permeation, (ii) to increase 
metabolic stability toward exo- and endopeptidases, and (iii) to promote rapid 
prodrug bioconversion.   
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Many hydrophilic peptides, opioid peptides included, are restricted to cellular 
permeation via the paracellular pathway.  During this route of permeation, the 
hydrophilic molecules travel through aqueous pores in between the cells.  These pores 
are regulated by tight junctions that range in size from 7-9 Ǻ.24  Quite naturally, these 
pores restrict permeation based on the size and charge of the peptides.24,25  The linear 
opioid peptide DADLE does have desirable paracellular characteristics (hydrophilic 
and charged at physiological pH ).  However, DADLE is significantly larger in size 
(MW = 570 DA) than is typical for paracellular penetration (< 300 DA) and, 
therefore, has very low intestinal permeation.25,26   
Peptides that are hydrophobic, exhibit no charge, and have a low hydrogen-
bonding potential can cross biological barriers via the transcellular pathway.27  
During this route of permeation, molecules travel through the cell membrane, and 
higher molecular weight molecules can be tolerated via the transcellular pathway.  
Based on DADLE’s charged and hydrophilic nature as well as the multiple hydrogen 
bond donors and acceptors present, the transcellular permeation of DADLE would be 
predicted to be low.  For DADLE to become a viable drug, the cellular permeation 
must be improved.   
A successful cyclic peptide prodrug should be able to cross biological 
membranes with little to no metabolic degradation.  The metabolic stability issue of 
peptide drugs has largely been resolved through structural modifications by medicinal 
chemists.19,28  The development of DADLE is an example of this.  Modifications to 
the amino acid sequence and stereochemistry of [Leu5]-Enk (H-Tyr-Gly-Gly-Phe-
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Leu-OH) affords DADLE (H-Tyr-D-Ala-Gly-Phe-D-Leu-OH).  The replacement of 
glycine with alanine at the second residue of the peptide and modification of 
stereochemistry (L-amino acids to D-amino acids) at the second and fifth residues 
were shown to greatly increase stability towards amino- and carboxypeptidases.7  
Cyclic peptide prodrugs were designed to further increase the metabolic stability of 
DADLE by enhancing stability toward exo- and endopeptidases.  This was 
accomplished with the cyclic structure itself, since the N- and C-termini are “masked” 
in the cyclic prodrugs.  The cyclic design did provide DADLE prodrugs with greater 
stability against exo- and endopeptidases.29,30     
Having a stabilized peptide is only one aspect to consider with a peptide 
prodrug; the promoiety and bioconversion of the prodrug must also be taken into 
account.  Once across the membrane barrier, the prodrug should undergo a 
spontaneous or rapid enzyme-mediated biotransformation to release the active 
peptide.  Much of the bioconversion depends on the choice of promoiety.  However, 
the choice of promoiety also affects the physicochemical properties of the molecule 
(i.e., charge, conformation, lipophilcity, and hydrogen-bonding potential), which in 
turn affect the cellular permeation.  In an attempt to improve the physicochemical 
properties and, ultimately, the cellular permeation of opioid peptides, the Borchardt 
and Siahaan laboratories have developed cyclic peptide prodrugs of the opioid 
peptide DADLE.  In the cyclic prodrugs, the N- and C-termini of the peptide are 
joined via promoiety linkers.17,18,31  Four new promoieties have been developed for 
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this task: phenylpropionic acid (PPA),18 (acyloxy)alkox (AOA),17 coumarinic acid 
(CA),18 and oxymethyl-modified coumarinic acid (OMCA)31 linkers (Figure 1.1).   
 
 
1.3 PHYSICOCHEMICAL PROPERTIES OF CYCLIC PRODRUGS OF 
OPIOID PEPTIDES 
Prodrugs can be used to enhance the pharmaceutical qualities and overall 
“drugability” of a moleule.32  In making prodrugs of DADLE, the peptide was 
incorporated into a cyclic structure containing a promoiety.  Model peptides, [Leu5]-
Enk, and DADLE were used to evaluate the physicochemical properties of these new 
prodrugs.  Changes in physicochemical properties of the molecules were seen upon 
cyclization and can be related to lipophilicity and solution conformation.  Ultimately, 
the goal of creating cyclic DADLE prodrugs was to enhance the physicochemical 
properties of the prodrugs resulting in increased membrane permeation compared to 
DADLE.   
 
1.3.1 Liophilicity 
The lipophilicity of DADLE is significantly increased by intramolecular 
cyclization and addition of a lipophilic promoiety.  The cyclic prodrugs are uncharged 
as a result of linking the N- and C- termini of the peptide.  Addition of lipophilic 
linkers (PPA, CA, and OMCA) contributes to the increased lipophilicity of the cyclic 
prodrugs, which is important to their transcellular permeation.  During transcellular 
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Figure 1.1.  Structure of cyclic prodrugs of DADLE 
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permeation, hydrophobic molecules travel through the cell membrane and interact 
with the lipid biolayer.  The membrane interaction potentials of the cyclic prodrugs 
and linear peptides were measured using immobilized artificial membranes (IAM) or 
estimated using cLogP values.   
In measuring membrane interaction potentials, the interaction of the molecule 
with an IAM column gives an estimation of the combined effects of charge, polarity, 
and hydrogen-bonding potential.  If a molecule is too hydrophilic, it will not interact 
with the lipophilic cell membrane (low interaction potentials).  This signals that the 
molecule will not be able to cross the cell membrane in a transcellular fashion.  
Linear peptides, [Leu5]-Enk, and DADLE were found to have low membrane 
interaction potentials.17,18  Cyclic prodrugs of [Leu5]-Enk and DADLE were found to 
have enhanced membrane interaction potentials compared to their linear counterparts.  
The PPA- and CA-cyclic prodrugs exhibited sevenfold to 20-fold increased 
interaction potentials over the linear peptides,18 and AOA-cyclic prodrugs showed 
four to eightfold increased interaction potentials over the linear peptides.17   
More recently, membrane interaction potentials have been replaced with 
cLogP values.  cLogP values are computer-generated estimates of lipophilicity.  The 
calculations are based on structure, polar surface area, molecular size, and charge of 
the molecule.  The more lipophilic a molecule, the higher the cLogP value.  The 
lipophilicity of a molecule can be used to relate directly to cell permeation.  A low 
cLogP value would indicate that the molecule is not lipophilic enough to permeate the 
cell membrane via the transcellular route, but too high a cLogP value (typically 
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greater than 5) would indicate that the molecule is too lipophilic and is likely to get 
stuck in the lipid membrane.  In the popular “rule of five” by Lipinski, having a 
cLogP value less than five is considered an important criterion in the drugability of a 
molecule.33  DADLE was found to have a low cLogP value (-0.32), indicating a very 
low lipophilicity.  The CA- and OMCA-DADLE cyclic prodrugs were found to have 
cLogP values of 4.96 and 4.95, respectively.31  The higher cLogP values of the CA- 
and OMCA-cyclic prodrugs indicate a more favorable lipophilicity for transcellular 
permeation.   
 
1.3.2 Solution Conformation 
Solution conformation and molecular size are important physicochemical 
properties and can help to predict cell membrane permeation.  Passive diffusion 
becomes increasingly difficult as the molecule becomes larger.25,34-38  To gauge the 
molecular size of the cyclic prodrugs, NMR diffusion coefficients and molecular 
surface area calculations were determined.  [Leu5]-Enk and DADLE displayed 
diffusion coefficients similar to those of the cyclic prodrugs (PPA-, AOA-, and  
CA-).17,18  Molecular surface area calculations showed DADLE , CA-DADLE, and 
OMCA-DADLE have areas similar in size.31  These calculations show that, even with 
the addition of a linker to the cyclic prodrugs, the linear peptides and cyclic peptide 
prodrugs are comparable in size.   
It is evident from the size measurements that the peptide prodrugs become 
more compact upon cyclization.  This is a result of a distinct solution structure.  For 
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example many of the cyclic prodrugs contain a β-turn structure.31,39-41  This defined 
secondary structure has been shown to possess intramolecular hydrogen bonds.  The 
result of this is twofold: (i) the intramolecular hydrogen bonding pulls the molecule 
into a tighter conformation, effectively reducing the molecular size, and (ii) increased 
intramolecular hydrogen bonding results in decreased opportunity for prodrug-solvent 
hydrogen bonding and a lower hydrogen-bonding potential overall.  This illustrates 
that the unique solution structure of cyclic prodrugs helps to increase the lipophilicity 
of the molecule.  Compared to linear peptides, the cyclic prodrugs are uncharged, 
more lipophilic, and have a decreased hydrogen-bonding potential.  These 
physicochemical properties determine, in part, the pathway and extent of passive 
permeation across biological barriers.   
 
 
1.4 BIOPHARMACEUTICAL PROPERTIES OF CYCLIC PRODRUGS OF 
OPIOID PEPTIDES 
The goal in the development of cyclic DADLE prodrugs was to design 
prodrugs that are orally absorbed and localize in the brain.  Physicochemical 
characteristics important to permeation across biological barriers [i.e., intestinal and 
blood brain barrier (BBB)] are size, charge, lipophilicity, and hydrogen-bonding 
potential.  Cyclization of the peptides has produced cyclic prodrugs with favorable 
physicochemical properties that could potentially lead to enhanced membrane 
permeation.  Investigations into cell permeability (in vitro and in vivo), metabolic 
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stability, and pharmacokinetics further detail the drug-like characteristics of the cyclic 
prodrugs and overall oral bioavailability.   
 
1.4.1 In Vitro Cellular Permeation 
A major barrier for orally delivered drugs is the intestinal mucosa.  Looking at 
the physicochemical properties and structural features of cyclic prodrugs, one would 
expect them to have better transcellular permeation than linear peptides.  However, 
DADLE was found to be from 36- to 52-times more permeable than AOA-DADLE in 
Caco-2 cell monolayers.42  The intrinsic permeation [apical (AP) to basolateral (BL)] 
of DADLE demonstrated an apparent permeability coefficient (Papp) of 7.80 × 108 
cm/s, but the cyclic prodrug AOA-DADLE had a much lower value of 1.86 × 108 
cm/s.42  This suggests that cyclic prodrugs are substrates for apically polarized efflux 
transporters42-45, which can limit transcellular permeation.46,47  Additional evidence 
that cyclic prodrugs are substrates for efflux transporters was seen by using Madin-
Darby canine kidney cells (MDCK) transfected with human P-gp (MDR1) or 
multidrug resistance protein-2 (MRP2).43-45  These studies showed that the intrinsic 
permeation of the cyclic prodrugs was recovered with the use of P-gp and/or MRP 
inhibitors.   
There is extensive literature available on transporters and their role in drug 
disposition.37,48-57  Currently however, there is limited information on substrate 
activity of cyclic prodrugs for specific efflux transporters.  The Borchardt lab has 
determined cyclic prodrug substrate specificity for MDR1 and MRP2.  AOA-DADLE 
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is primarily a substrate for MDR145, while CA- and OMCA-DADLE are substrates 
for both MDR1 and MRP2.43,44  Cells used in these studies were found to have high 
levels of MDR1 expression, very low levels of MRP2 present, and no detectable 
amount of BCRP.44,45  This suggests that differentiation of co-substrates for various 
efflux transporter systems (i.e., MDR1/BCRP, MPR2/BCRP or MDR1/MPR2/BCRP) 
would be unlikely.  Using our knowledge of efflux transports in biological barriers, 
Caco-2 and MDCK cell permeation experiments can help predict oral bioavailability 
of DADLE in vivo.  Poor in vitro permeation suggests that cyclic prodrugs would 
most likely possess characteristics that could lead to difficulties in vivo.   
 
1.4.2 In Situ Intestinal Mucosal Perfusion 
Low transcellular permeation of cyclic prodrugs in Caco-2 cells suggests that 
cyclic prodrugs would display low oral absorption.  To determine the intestinal 
permeation of DADLE and cyclic prodrugs in vivo, in situ rat intestinal perfusion 
experiments were conducted.58-60  In these experiments, a section of intestine was 
isolated and test compound was directly infused into the intestine.  The mesenteric 
vein was cannulated to collect blood samples from the isolated intestinal region.  
Blood and perfusate samples were collected continuously and analyzed for the 
presence of cyclic prodrug and DADLE.  The in situ intestinal perfusion experiments 
showed that DADLE is four times more able to permeate than AOA-, CA- or OMCA-
DADLE.60  These results parallel the in vitro Caco-2 intestinal cell permeation data, 
which confirm that DADLE permeates better than the cyclic prodrugs.42,43,61   
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The role of efflux transporters in restricting intestinal mucosal permeation of 
the cyclic prodrugs was determined using known P-gp inhibitors [PSC-833, 
cyclosporine (CyA), GF-120918].  An in situ rat ileum perfusion model and an in 
vitro cell culture model (Caco-2 cells) were used in these studies.  The apparent 
permeability coefficients of the cyclic prodrugs were low in both models.  However 
in the presence of inhibitors, the intestinal permeation of cyclic prodrugs was 
significantly increased.59  Interestingly, the potency of the inhibitors differed in the 
two intestinal permeation models.  The Caco-2 cell culture studies showed the 
inhibitors to be equipotent, but the in situ rat intestinal perfusion model showed PSC-
833 to be significantly more potent than the other inhibitors.59  This suggests that in 
the intestinal mucosa cyclic prodrugs are substrates for multiple efflux transporters, 
which are inhibited differently by P-gp inhibitors.  The difference between the two 
models is not surprising seeing as the stock Caco-2 cells used were shown to lack 
some of the efflux transporters found in vivo.59  Overall, these data clearly 
demonstrate the influence that efflux transporters have on restricting the permeation 
of cyclic prodrugs across the rat intestinal mucosa.  
 
 
1.4.3 In Situ Brain Perfusion 
Based on low transcellular permeation across MDCK-MDR1 cell 
monolayers,43-45 one would expect very limited BBB permeation of cyclic prodrugs.  
BBB permeability studies of DADLE and cyclic prodrugs were conducted in vivo 
 14
using an in situ rat brain perfusion model.62,63  In these experiments, test compound 
was infused directly into the brain via the carotid artery.  Brain tissue samples were 
collected and analyzed for the presence of cyclic prodrug and DADLE.  These 
experiments show that, in the absence of a P-gp inhibitor (GF-120918), DADLE and 
cyclic prodrugs have very similar BBB permeation, despite their different 
physicochemical characteristics.  DADLE has a BBB apparent permeability 
coefficient (PB) of 0.5 × 107 cm/s and cyclic prodrugs have PB values ranging from 
0.4 - 1.2 × 107 cm/s. 62  The data suggest that both DADLE and cyclic prodrugs have 
limited BBB permeation due to efflux transporters.  To ascertain the role of efflux 
transporters in vivo, the permeation of DADLE and cyclic prodrugs was determined 
in the presence of GF-120918.62  The PB values of the cyclic prodrugs were 
consistently higher, from 50 to 450- times, in the presence of GF-120918.  However, 
DADLE did not show increased BBB permeation in the presence of inhibitor.  This 
suggests that the poor BBB permeation of DADLE is not due to efflux transporters 
but is most likely the result of poor physicochemical properties.  Interestingly, cyclic 
prodrugs possess more favorable physicochemical properties than DADLE but are 
substrates for P-gp.  Overall, cyclic prodrugs have limited BBB permeation in vivo.  
These data imply that changing the structure of the peptides to form cyclic prodrugs 
transforms the molecules into P-gp substrates.   
The role of P-gp in restricting BBB permeation of the cyclic prodrugs was 
investigated using known P-gp inhibitors (PSC-833, CyA, GF-120918).64  Two 
models were used in the studies: the in situ perfused rat brain model and an in vitro 
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cell culture model (MDCK-MDR1 cells).  Cyclic prodrugs exhibited low permeation 
in both models but, in the presence of inhibitors, the BBB permeation was 
significantly increased.  The in vitro BBB model showed the inhibitors to be 
approximately equipotent, while the in vivo BBB model showed GF-120918 to be 
slightly more potent than CyA and PSC-833.64  This suggests that cyclic prodrugs are 
substrates for multiple efflux transporters, which are inhibited differently by P-gp 
inhibitors.  Overall, it was established that (i) P-gp is a major factor in restricting 
BBB permeation both in vitro and in vivo, (ii)  in vitro BBB model successfully 
predicts the in vivo BBB permeation in rat, and (iii) MDR1 and the equivalent rat P-
gp have similar substrate specificities.64  It is clear that efflux transporters play a role 
in restricting the permeation of cyclic prodrugs across the rat BBB.     
 
1.4.4 Metabolic Stability 
Metabolic stability is an important biopharmaceutical property.  The success 
of cyclic prodrugs depends not only on their permeation, but also on the molecule 
reaching the site of action intact.  Cyclic prodrugs show low cell permeation 
characteristics in vitro and in vivo related to their interaction with P-gp.  It has been 
proposed that there is a strong correlation between the substrate specificity of P-gp 
and cytochrome P450-3A4 (CY3A4).48,65-68  Thus, it is reasonable to suspect that 
cyclic prodrugs would also be substrates for phase I metabolizing enzymes.  Liver 
microsomes were used to ascertain the importance of phase I metabolizing enzymes 
in the stability of the cyclic prodrugs.60  DADLE was found to be stable in the 
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presence of rat liver microsomes, but AOA-, CA-, and OMCA-DADLE were highly 
unstable.  Less than 18% of cyclic parent remained after a 30-min incubation.60  
Inhibitors were used to probe the stability of the cyclic prodrugs under these 
conditions.  Cyclic prodrug disappearance was found to be largely dominated by 
cytochrome P450 oxidation.  In the presence of ketoconazole, a known CYP3A4 
inhibitor, greater than 50% of the parent remained.60  The data clearly indicate the 
importance of P450 metabolizing enzymes to the stability of the cyclic prodrugs and 
suggests that oral bioavailability of the cyclic prodrugs would be limited in vivo by 
first-pass metabolism in the liver.   
 
1.4.5 In Vivo Pharmacokinetics 
Modifying DADLE through cyclization and addition of a linker could lead to 
potential changes in drug-like properties (i.e., solubility, bioconversion, metabolism, 
clearance).  Important biopharmaceutical properties of cyclic prodrugs were 
characterized after i.v. administration.  The stability, bioconversion, brain-uptake, and 
clearance of the cyclic prodrugs were considered.   
 
1.4.5.1 In Rat 
Disappearance of cyclic prodrugs and DADLE from systemic circulation was 
found to be rapid in rat.  Improved plasma half-lives were observed for cyclic 
prodrugs compared to DADLE.  DADLE showed a t1/2plamsa of 5 min, while CA-, 
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OMCA-, and AOA-DADLE had plasma half-lives of 24 min, 18 min, and 14 min, 
respectively.69   
Bioconversion in vivo paralleled in vitro bioconversion data (Figure 1.2).69  
For AOA-DADLE, the labile ester bond was cleaved via an esterase-catalyzed 
reaction to form intermediate I, which underwent further chemical degradation to 
release DADLE.  In the case of AOA-DADLE, intermediate I was not detected; this 
implies rapid degradation to DADLE, CO2, and formaldehyde.  The bioconversion of 
CA-DADLE  proceeded through intermediate II, and the OMCA-DADLE 
bioconversion profile proceeded through two intermediates (II and III).  For OMCA-
DADLE, only intermediate II was detected.  This suggests that the rate-limiting step 
for CA- and OMCA-DADLE is the release of DADLE, while hydrolysis of the ester 
bond is the rate-limiting step for the bioconversion of AOA-DADLE.   
Cyclic prodrugs and DADLE show very low uptake into rat brain after i.v. 
administration.69  Contrary to their permeation-favorable design, cyclic prodrugs did 
not show better permeation than DADLE.  However, DADLE was detected in rat 
brain after the i.v. administration of cyclic prodrugs.  This is evidence of prodrug-to-
DADLE bioconversion in rat brain.   
The pathways of elimination for cyclic prodrugs and DADLE were found to 
differ.  Cyclic prodrugs were quickly eliminated from systemic circulation with a 
significant amount removed through biliary clearance and a minor percentage via 
renal clearance.69  Experiments using bile duct-cannulated rats showed 46% of AOA-
DADLE, 26% of CA-DADLE, and 38% of OMCA-DADLE was recovered in the bile  
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Figure 1.2.  Bioconversion of AOA-, CA-, and OMCA-DADLE 
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after a 2-hr sample period.69  In contrast, DADLE showed only a small recovery in 
bile and urine.  This implies that metabolism by exo- and endopeptidases is a major 
elimination route for DADLE, while cyclic prodrugs are eliminated by the liver.   
 
1.4.5.2 In Guinea Pig 
The bioconversion of OMCA-DADLE was found to be much faster in rat 
plasma than in rat brain; however, in guinea pig, bioconversion was faster in brain 
than plasma.69,70    Since the cyclic prodrugs of DADLE were designed to target the 
brain, an attempt to optimize the bioconversion of OMCA-DADLE was undertaken 
with the synthesis of amino acid-modified prodrugs of OMCA-DADLE.41  
Investigations into the bioconversion of these cyclic prodrugs led to two 
conclusions70: (i) the prodrug bioconversion profile in human biological media 
correlated better with the stability profile observed in guinea pig than in rat and (ii) 
the prodrugs containing diastereomers of DADLE had more favorable brain-to-
plasma conversion profiles than DADLE itself. 
Pharmacokinetic studies were undertaken with OMCA-DADLE (OMCA-[D-
Ala2,D-Leu5]) and OMCA-[D-Ala2,Leu5]-Enk.  In guinea pig, OMCA-cyclic 
prodrugs were found to disappear rapidly after i.v. administration.  OMCA-DADLE 
showed very similar pharmacokinetic parameters in guinea pig and rat, but there was 
a significant species difference observed for OMCA-[D-Ala2,Leu5]-Enk.71  OMCA-
[D-Ala2,Leu5]-Enk was found to be more stable in guinea pig than in rat.  A plasma 
half-life of 2.7 min was seen in guinea pig, but OMCA-[D-Ala2,Leu5]-Enk was not 
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detected in rat plasma.71  The prodrug bioconversion profile for both OMCA-cyclic 
prodrugs in guinea pig plasma was found to be the same as the bioconversion profile 
in rat plasma.  Intermediate II (Figure 1.2) was detected, but in levels too low to 
quantify. 
There was a significant species difference in brain permeation of OMCA-
prodrugs after i.v. administration.  OMCA-DADLE showed an 80-fold increase in 
permeation across the BBB of guinea pig compared to the permeation across the BBB 
of rat.71  The dramatically increased ability of OMCA-DADLE to penetrate the BBB 
in guinea pig can most likely be attributed to different substrate specificities of the 
efflux transporters that are expressed in guinea pig and rat BBB.  This is a reasonable 
assumption since other studies have documented species differences in efflux 
transporter disposition.72-74  Linear peptide was detected in guinea pig brain after the 
i.v. administration of OMCA-cyclic prodrugs.  The prodrug-to-linear peptide 
bioconversion was 8.5 times higher in guinea pig brain than in rat brain.71   
OMCA-cyclic prodrugs were found to be quickly eliminated in guinea pig.  
Biliary clearance, however, was not the major elimination route.  Only 4% of the 
OMCA-cyclic prodrugs were recovered from bile in guinea pig compared to 40% 
recovery in rat.71  This 10-fold decrease in biliary clearance is attributed to species 
differences in substrate specificity of the efflux transporters expressed in the liver.  To 
investigate cyclic prodrug elimination in guinea pig, in vitro liver microsomal studies 
were performed.  It was found that OMCA-DADLE cyclic prodrugs showed a greater 
increase in phase I metabolism in guinea pig liver microsomes than in rat liver 
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microsomes.71  This suggests that the reduced bile clearance in guinea pig is, in part, 
due to increased phase I metabolism.   
 
 
1.5 CONCLUSIONS 
In the past 10 years, the development and characterization of cyclic DADLE 
prodrugs has been intriguing.  Compared to DADLE, the cyclic prodrugs are 
uncharged and hydrophobic and have a unique solution structure with a lower 
hydrogen-bonding potential.  These physicochemical properties are advantageous for 
increased membrane permeation.  Permeation by the cyclic prodrugs, however, is 
limited by their substrate specificity for efflux transporters.  This translates into low 
intestinal mucosal and BBB permeability in vitro and in vivo.  While low membrane 
permeation contributes to the overall low bioavailability of these compounds, the 
pharmacokinetic profile is also responsible.  The cyclic prodrugs rapidly disappear 
from systemic circulation in rat and guinea pig.  There is very little brain uptake in 
rat, but a significant amount of cyclic prodrug is seen in guinea pig brain after i.v. 
administration.  Cyclic prodrugs are eliminated by the liver, but the extent of biliary 
clearance is highly variable and dependent on animal species.  Cyclization of the 
molecules transforms the peptides into substrates for cytochrome P450 enzymes.  
Oral bioavailability of cyclic prodrugs is most significantly limited by poor 
membrane permeation (i.e., intestinal and BBB), but first-pass effects in the liver and 
phase I oxidative metabolism are also restrictive factors.   
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1.6 OBJECTIVES AND SPECIFIC AIMS 
Poor pharmaceutical properties have slowed the development of opioid 
peptides into drug products.29,75,76  Especially troubling is low permeation through 
biological barriers.  Our laboratory has designed cyclic prodrugs to significantly alter 
the physicochemical properties of the peptides.  The opioid peptide prodrugs were 
designed to be uncharged, stable to exo- and endopeptidases, and more lipophilic, 
thereby potentially increasing membrane permeation.  This has been accomplished 
using a cyclic structural design in which the N- and C-termini are joined.  Cyclization 
of the peptides was found to bring about more favorable physicochemical 
properties,17,18,31 but did not enhance membrane permeation.44,45,59  Cyclic prodrugs 
were found to be substrates for efflux transporters and phase I oxidative metabolizing 
enzymes.44,45,59,60  Considering that oral bioavailability is largely affected by these 
two factors, the objective of my dissertation research was to design metabolically 
stable cyclic prodrugs (Figure 1.3) and investigate their biopharmaceutical properties. 
This objective was accomplished through the following specific aims: 
 
Specific Aim 1:  To determine the metabolically labile sites of a parent cyclic prodrug 
containing a coumarinic acid linker (CA). 
Specific Aim 2:  To design and synthesis more metabolically stable CA-cyclic 
prodrugs.  
Specific Aim 3: To evaluate the physicochemical properties and solution 
conformation of the new cyclic prodrug analogs. 
 23
Specific Aim 4: To evaluate the in vitro and in vivo permeation of the new cyclic 
prodrug analogs. 
 
 
                                        Tyr-D-Ala-Gly-Phe-D-Leu (DADLE) 
                                        Tyr-D-Ala-Gly-Cha-D-Leu ([Cha4,D-Leu5]-Enk) 
                                        Tyr-D-Ala-Gly-Cha-D-Ala ([Cha4,D-Ala5]-Enk) 
 
 
Figure 1.3. Structure of CA-DADLE and cyclic prodrug analogs 
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Chapter 2 
 
Metabolic Stability of CA-DADLE and Identification of Its Metabolites 
 
 
 
 
 
 
 
 
 
 36
2.1 INTRODUCTION 
Peptide and peptidomimetics have long been evaluated for therapeutic use due 
to their intrinsic receptor specificity and promising pharmacological properties.1-5  
Unfortunately, the development of these peptides into viable oral dosage forms has 
been limited by their undesirable physicochemical properties, including poor 
intestinal mucosa permeation and enzymatic instability.6-9  The challenge in making 
orally viable opioid peptides lies in improving the physicochemical properties of the 
peptides while maintaining their high affinity for opioid receptors.   
In an attempt to improve membrane permeability of opioid peptides, we have 
developed cyclic peptide prodrugs of the opioid DADLE (H-Tyr-D-Ala-Gly-Phe-D-
Leu-OH) in which the N- and C-termini of the peptide are joined via chemical 
linkers, specifically the coumarinic acid linker (CA) (Figure 2.1).  The resultant 
cyclized prodrugs are uncharged at physiological pH and exhibit unique solution 
structures.  The solution structure of CA-DADLE has been found to contain a 
conformationally restricting β-turn, which enhances intramolecular hydrogen-bonding 
within the molecule.10  The resultant cyclized prodrugs are uncharged, lipophilic, and 
exhibit lower hydrogen-bonding potential than DADLE; thus, they should display a 
improved membrane permeability.11  These cyclic DADLE prodrugs, however, did 
not show the expected increased cell permeation.  Using cell culture models, it has 
been determined that the cyclic prodrugs are substrates for apically polarized efflux 
transporters [i.e., P-glycoprotein (P-gp)] in the intestinal mucosa.10,12-16  Considering  
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Figure 2.1.  Structure of cyclic opioid peptide prodrug CA-DADLE 
 
 
 
 
 
 
 
 
OO
HN
Tyr DAla Gly Phe DLeu
O
 38
the fact that many P-gp substrates are also substrates for phase I enzymes,17-20 the 
oxidative metabolism of these prodrugs has come into question.   
CA-DADLE was used to investigate the metabolism of cyclic peptide 
prodrugs.  Metabolic stability of CA-DADLE was evaluated in the presence of rat 
liver microsomes (RLM), guinea pig liver microsomes (GPLM), human liver 
microsomes (HLM), and human recombinant cytochrome P450 (hCYP3A4).  
Oxidative metabolites of CA-DADLE under these in vitro conditions have also been 
identified.   
 
 
2.2 MATERIALS AND METHODS 
2.2.1 Materials 
The cyclic prodrug CA-DADLE was synthesized in our laboratory following 
described procedures.8,21  Pooled male Sprague-Dawley rat liver microsomes (RLM), 
pooled male Hartely albino guinea pig liver microsomes (GPLM), pooled human liver 
microsomes, mixed gender microsomes(HLM), and human recombinant cytochrome 
P450 3A4 expressed in bactosomes (hCYP3A4) were purchased from Xenotech, LLC 
(Lenexa, KS).  DADLE, diethyl p-nitrophenyl phosphate (paraoxon, approx. 90%), 
ketoconazole, β-nicotinamide adenine dinucleotide phosphate (β-NADPH; reduced 
form), sodium phosphate monobasic (NaH2PO4) and sodium phosphate dibasic 
(Na2HPO4,) were obtained from Sigma-Aldrich.  All chemicals and solvents (HPLC 
grade) were used as received.   
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2.2.2 Metabolic Stability 
Metabolic stability studies of the cyclic prodrug were preformed using RLM, 
GPLM, HLM and hCYP3A4.  These biological media were chosen as a result of the 
“prodrug conversion profile” of the cyclic peptide prodrugs in the presence of various 
biological media and tissue homogenates previously reported by our laboratory.22  
The cyclic prodrug (2.5 µM) was incubated for 30 min at 37°C in the presence of 
NADPH (1 mM) in sodium phosphate buffer (100 mM, pH 7.4) with or without 
inhibitors (inhibitors: 100 µM paraoxon, an esterase inhibitor, and 5 µM 
ketoconazole, a CYP3A4 inhibitor).  The assay was stopped with 100 µL of methanol 
and 750 µL of acetonitirile, vortexed, and the debris removed with centrifugation 
(13,000 × g for 15 min).  The supernatant (500 µL) was evaporated to dryness 
(Centrivap concentrator, Labconco, Kansas City, MO) and the pellet was dissolved in 
100 µL of 25% acetonitrile.  Control samples were run with the addition of 100 µL of 
methanol to the 500 µL phosphate buffer solution (100 mM, pH 7.4) containing 1 
mM NADPH and 2.5 µM cyclic prodrug.  After the addition of the liver 
microsomes/recombinant 3A4, 750 µL of ACN was quickly added and the sample 
was processed as stated above.  The amount of substrate remaining was calculated by 
dividing the average substrate peak area by the average substrate peak area in the 
control sample.  Statistics were preformed with Sigma Stat 3.5 using a one-way 
ANOVA with a Hohn-Sidik multiple comparison. 
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2.2.3 Metabolite Identification 
Phase I oxidative metabolites were identified using the same biological media 
as in the metabolic stability studies.  The cyclic prodrug (2.5 µM) was incubated for 
15 min at 37°C in the presence of NADPH (1 mM) in sodium phosphate buffer (100 
mM, pH 7.4).  The assay was stopped with 100 µL of methanol and 750 µL of 
acetonitrile, vortexed, and the debris removed by centrifugation (13,000 × g for 15 
min).  The supernatant (500 µL) was evaporated to dryness (Centrivap concentrator, 
Labconco, Kansas City, MO) and the pellet was dissolved in 100 µL of 25% 
acetonitrile.   
 
2.2.4 Analytical Methods 
High-performance liquid chromatography with tandem mass spectrometry 
detection (LC/MS/MS) was employed using a Quattro Micro triple quadrupole mass 
spectrometer.  Liquid chromatography was conducted using a Waters 2690 HPLC 
system. The separation was preformed on a Vydac C18 column (50 × 1.0 mm i.d., 
300 Å).  The cyclic peptide prodrugs were isolated using a gradient from 5% to 95% 
of solvent B [solvent A: water with 0.1% formic acid (v/v) and solvent B: 
acetronitrile with 0.1% formic acid (v/v)].  The total run time was 20 min with a flow 
rate of 0.2 mL/min (3 min gradient from 5% to 40% B; 3 min gradient from 40% to 
95% B; 2 min at 95%; 2 min return to 5% B; 10 min equilibration at 5% B).  The 
eluate was analyzed by electrospray ionization (ESI) in positive mode.  Precursor 
scans were used for detection of fragmentation with m/z = 86.6, 120.1, 136.2, 207.0.  
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Multiple reaction monitoring (MRM) scans were used to determine oxidative 
metabolites with the following m/z transitions: parent > 102.6, 136.1, 152.2 and 223.0 
with parent m/z set at: 714.4 (CA-DADLE + OH).  MRM scans were also used to 
determine the metabolic stability.  Detection of the tyrosine common product ion (un-
oxidized) was used to qualitatively determine the amount of cyclic parent remaining.  
The m/z transition of parent > 136.1 with the parent m/z set at 698.0 (CA-DADLE) 
was used.   
 
 
2.3 RESULTS 
2.3.1 Metabolic Stability 
DADLE and cyclic CA-DADLE show significantly different metabolic 
stability profiles under the conditions studied.  The metabolic stability of both 
DADLE and CA-DADLE has been investigated in the presence of RLM, GPLM, 
HLM, and hCYP3A4 with and without inhibitors.  In the case of the liver 
microsomes, paraoxon, an esterase B inhibitor, as well as ketoconazole, a cytochrome 
P450 inhibitor, have been used.  The metabolic stability assay conducted with 
hCYP3A4 contains only active P450 enzymes with no esterases present.  For this 
reason only ketoconazole is used as an inhibitor in these assays.  The studies indicate 
that, in the presence of RLM, DADLE has 100% parent compound remaining when 
no inhibitors are present (Figure 2.2).  CA-DADLE, however, shows only 9% of the 
cyclic parent remaining with no inhibitors present (Figure 2.2).  The presence of an  
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Figure 2.2.  Metabolic stability of CA-DADLE in the presence of rat liver 
microsomes.  (*P < 0.001) 
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esterase inhibitor, paraoxon, did little to enhance the metabolic stability of the cyclic 
prodrug, with only 13% of the cyclic parent remaining.  The addition of ketoconazole, 
a cytochrome P450 inhibitor, produces a significant increase (53 %) in cyclic parent.  
A combination of both inhibitors results in 59% of the CA-DADLE being detected. 
In the GPLM assays, DADLE again shows a significant amount (90%) of 
parent drug remaining under all conditions (Figure 2.3).  With no inhibitors present, 
only 6% of CA-DADLE remains (Figure 2.3).  Addition of paraoxon did little to 
enhance the amount of cyclic prodrug, with only 10% cyclic remaining after a 30-min 
incubation.  Significant increases in the amount of CA-DADLE remaining are seen 
with the addition of ketoconazole (43%) and the ketoconazole/paraoxon inhibitor 
combination (63%).      
The metabolic stability assays with HLM mirror the results of the other liver 
microsomal assays.  DADLE is stable under all conditions, showing greater then 89% 
of parent drug remaining without inhibitors and above 95% parent drug remaining 
with inhibitors (Figure 2.4).  Contrary to DADLE , CA-DADLE did not show high 
stability in the presence of HLM without inhibitors, showing only 15% of the parent 
drug remaining.  The metabolic stability of CA-DADLE dramatically increases with 
the addition of ketoconazole and the ketoconazole/paraoxon cocktail to 85% and 90% 
respectively, but remains low at 12% of parent drug remaining with the addition of 
paraoxon alone. 
Similar metabolic stability is seen in the presence of recombinant human 
hCYP3A4.  DADLE in the presence of hCYP3A4 shows 98% of the parent remaining  
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Figure 2.3.  Metabolic stability of CA-DADLE in the presence of guinea pig liver 
microsomes.  (*P < 0.001) 
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Figure 2.4.  Metabolic Stability of CA-DADLE in the presence of human liver 
microsomes.  (*P < 0.001) 
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Figure 2.5.  Metabolic stability of CA-DADLE in the presence of hCYP3A4.   
(*P < 0.001) 
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with and without inhibitors (Figure 2.5).  Without inhibitors, only 9% of CA-DADLE 
remains in the presence of hCYP3A4, but with the addition of ketoconazole, 78% of 
the cyclic parent remains (Figure 2.5). 
 
2.3.2 Metabolite Identification 
DADLE and the cyclic peptide prodrug CA-DADLE have been analyzed by 
LC/MS/MS, and for both compounds similar common immonium product ions 
resulted (Figure 2.6).  The m/z of these common product ions correlate with portions 
of the peptide that contain various amino acid fragments.  The fragmentation shows 
peaks at m/z of 86.6, 120.1, 136.2, and 207.0 (Figure 2.7).  These fragments are 
related to the amino acids of the peptide and have been identified as Leu, Phe, Tyr, 
and a di-peptide fragment, Tyr-Ala, respectively.  In the CA-DADLE spectra there is 
an additional product ion peak being identified at m/z 147 (Figure 2.6).  This fragment 
corresponds to the coumarin linker of the cyclic peptide prodrug compound.  With the 
common product ions being identified for both the linear and cyclic peptide 
molecules, the oxidative metabolites of the CA-DADLE could be determined.   
CA-DADLE was subjected to oxidative conditions, and the oxidative product 
ions were identified with multiple reaction monitoring (MRM).  The basic schematic 
for an MRM scan is presented pictorially in Figure 2.8.  Ions passing through 
Quadrupole 1 (Q1) are limited to the cyclic oxidized parent molecule containing one 
hydroxyl (m/z 714).  Using the optimized collision energy from the MS/MS scans, the 
cyclic compound is then fragmented and the oxidized product ions are investigated in  
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Figure 2.6.  Detection of the common product ions of linear DADLE and the 
cyclic peptide prodrug, CA-DADLE. 
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Figure 2.7.  Structures of the common ion products of DADLE and CA-DADLE. 
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Figure 2.8.  MRM scan design to detect oxidative metabolites of CA-DADLE.   
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quadrupole 3 (Q3).  The oxidized product ions being investigated have m/z of 102.6, 
136.1, 152.2, and 223.0.  The m/z of these ions correlate to the previous determined 
product ions with the addition of a hydroxyl (Figure 2.9).  Detection channels relating 
to each product ion m/z fragment are monitored and, if a peak is seen in a 
hydroxylated fragment channel, this is evidence that the product ion and, therefore, 
the corresponding amino acid, has been oxidatively metabolized.  It should be noted 
that with this method only the amino acid undergoing oxidation can be identified.  
The exact location of the hydroxyl on the amino acid has not been determined.  Also, 
when no oxidative metabolites are detected, an un-oxidized compound is identified, 
confirming the metabolic stability of either DADLE or CA-DADLE.   
The metabolite identification studies correlate well with the metabolic 
stability studies.  DADLE is metabolically stable under the four oxidative conditions 
studied; RLM, GPLM, HLM, and hCYP3A4 show no oxidative metabolites under 
these conditions (Figure 2.10).  Confirmation of the metabolically stable DADLE is 
established in the sample by evidence of the presence of un-oxidized product ions.  
The metabolism of CA-DADLE has been studied under the same oxidative conditions 
but yields very different results.  In the presence of rat liver microsomes and guinea 
pig liver microsomes, two oxidative products are observed, with the parent compound 
being hydroxylated on either the Tyr1 or Phe4 amino acid (Figure 2.11,2.12).  In 
contrast, human liver microsomes give evidence of hydroxylation only at one amino 
acid position, the Phe4 amino acid (Figure 2.13).  Metabolism of CA-DADLE in the 
presence of hCYP3A4 reveals significant oxidation only at the Phe4 amino acid  
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Figure 2.9.  Possible oxidative product ions of CA-DADLE.   
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Figure 2.10.  MRM Scan of DADLE metabolism in the presence of liver microsomes 
and hCYP3A4. 
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Figure 2.11.  MRM scan of CA-DADLE metabolism in the presence of rat liver 
microsomes.   
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Figure 2.12.  MRM scan of CA-DADLE metabolism in the presence of guinea pig 
liver microsomes. 
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Figure 2.13.  MRM scan of CA-DADLE metabolism in the presence of human liver 
microsomes. 
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Figure 2.14.  MRM scan of CA-DADLE metabolism in the presence of hCYP3A4. 
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Figure 2.15. MRM Scan of the CA-DADLE reveals no significant metabolism at the 
coumarinic acid linker. 
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position, similar to what has been seen in the presence of human liver microsomes 
(Figure 2.14).  Oxidative stability of the coumarinic acid linker has been confirmed, 
given that hydroxylated coumarin has not been identified under the conditions studied 
and only coumarin has been detected (Figure 2.15).  Oxidative addition of two or 
three hydroxyls is not seen under any of the conditions studied.   
 
 
2.4 DISCUSSION 
It has been previously reported by our laboratory that the cyclic peptide 
prodrugs of DADLE do not have the expected increased cell membrane 
permeability12-14 and that they are potentially subject to phase I oxidative metabolism.  
In vitro metabolic stability studies reveal DADLE to be metabolically stable in the 
presence of liver microsomes and recombinant human CYP3A4 bactosomes (Figures 
2.2-2.5), while CA-DADLE shows metabolic instability under the same conditions.  
In assays without the presence of inhibitors, less then 10% of the cyclic CA-DADLE 
remains (Figures 2.2-2.5).  This clearly indicates metabolic instability of CA-DADLE 
in the presence of these biological media.  In the presence of liver microsomes, 
addition of an esterase B inhibitor, paraoxon, did not result in a significant increase in 
the amount of cyclic parent recovered (Figures 2.2-2.4).  Seeing only a slight increase 
in the recovery of parent compound with the addition of paraoxon indicates that the 
metabolic instability of CA-DADLE is not likely due to a premature bioconversion of 
the ester prodrug.  The addition of ketoconazole, a cytochrome P450 inhibitor, 
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significantly increased the amount of cyclic parent recovered with recovery results 
between 50%-60% for each assay (Figure 2.2-2.5).  This strongly suggests that CA-
DADLE is metabolized by P450 enzymes.  There does not seem to be a large additive 
effect with respect to the two inhibitors, as the results from including both inhibitors 
mimic the results of ketoconazole alone.   
Metabolite identification studies have been performed to identify the 
susceptibility of the linker moiety and/or amino acid(s) to oxidative metabolism.  The 
metabolically stable DADLE shows no oxidative metabolites under all the conditions 
studied (Figure 2.10).  This demonstrates good agreement between the metabolic 
stability studies and the metabolite identification studies in relation to DADLE.  The 
more metabolically labile CA-DADLE, however, shows oxidative metabolites at 
either the Tyr1 or Phe4 amino acids in the presence of RLM or GPLM (Figures 
2.11,2.12) and Phe4 amino acid (Figure 2.13) in the presence of HLM.  Since CA-
DADLE  is seen to be metabolically labile in the presence of liver microsomes, it is 
not unexpected to find oxidative metabolites being formed under these conditions.  
Interestingly, the HLM yielded only one oxidative metabolite (at amino acid Phe4) 
while the rodent liver microsomes yielded two oxidative metabolites.  Since 
metabolic stability and, ultimately, oral bioavailability in humans is the goal in 
developing these cyclic peptide prodrugs, the diminished number of oxidative 
metabolites in the presence of HLM is encouraging.  In the presence of human 
recombinant cytochrome P450 containing only the 3A4 isozyme (hCYP3A4), 
oxidation only at Phe4 is detected (Figure 2.14).  This is consistent with the oxidative 
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metabolite of Phe4 resulting from the use of human liver microsomes.  Oxidation at 
solely the Phe4 amino acid position is therefore continuous for the two conditions 
containing human biological media.  This is compelling evidence that Phe4 is a labile 
site for human P450 oxidative metabolism.  Identification of oxidative metabolites of 
CA-DADLE complements the low percentage of cyclic compound recovered in the 
metabolic stability studies.  This confirms the fact that the degradation of CA-
DADLE results in part from the oxidative metabolism of the compound.   
The oxidative metabolism of the coumarinic acid linker has also been 
investigated.  Oxidation at the site of the coumarinic acid linker is considered a high 
probability due the known metabolic susceptibility of coumarin.23-25  Metabolite 
identification studies of CA-DADLE, however, show no detection of hydroxy-
coumarin (Figure 2.15), and the detection of unhydroxylated coumarin confirms the 
metabolic stability of the CA-linker moiety.  This indicates the oxidative metabolic 
stability of the CA-linker when it is incorporated as part of the cyclic peptide prodrug.   
The metabolic stability profile of CA-DADLE is quite unique.  The fact that, 
in all assays and under all conditions, DADLE shows metabolic stability reveals that 
it is not the peptide arm itself that is subject to metabolic instability.  The metabolic 
stability of the CA-linker moiety when incorporated within the cyclic peptide prodrug 
reveals that the addition of the linker itself is not the exclusive cause for the metabolic 
instability.  Since the CA-linker moiety within the cyclic peptide prodrug is stable and 
the peptide arm is stable as well, this leads to the conclusion that the overall solution 
conformation or rigidity of the molecule leads to the metabolic instability.  The 
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addition of the conformational restriction and decrease in rigidity appears to favor the 
molecule taking on a conformation that produces P450 substrate specificity.  This 
concept of increased/decreased rigidity leading to a change in substrate specificity is 
not unknown.  Opioid peptides themselves have been shown to have a diminished 
binding affinity to the opioid receptor upon cyclization, this is hypothesized as mainly 
due to the decrease in flexibility of the cyclic compound26-28.  It is most likely that the 
decreased flexibility introduced by the conformationally restricting β-turn is causing 
the increased substrate specificity in the cyclized CA-DADLE.  Overall, DADLE, 
being a linear peptide, is stable to liver microsomes and hCYP3A4, but the cyclic 
peptide prodrug CA-DADLE is metabolized under these conditions.   
It should be noted that an in-depth investigation into the oxidative metabolite 
formation has not been performed.  The focus of this study is to determine the amino 
acids that are sites of oxidative metabolism on CA-DADLE.  The goal is to modify 
these sites in order to design cyclic peptide prodrugs that are metabolically stable to 
cytochrome P450.    
 
 
2.5 CONCLUSION 
Cyclization of the peptide DADLE with a coumarinic acid linker has the 
promise of increasing cell permeation characteristics but as these studies reveal, at the 
cost of metabolic stability.  The new confined solution structure of cyclized DADLE 
makes the metabolically stable linear peptide vulnerable to oxidative metabolism at 
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Tyr1 and Phe4 on the peptide arm.  It is also evident from these studies that cyclization 
leads to cytochrome P450 metabolic instability in CA-DADLE.  Attempts will be 
made to redesign cyclic CA-DADLE via amino acid modification to increase its 
metabolic stability.     
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Chapter 3 
 
Synthesis of CA-DADLE Analogs and Characterization of Their 
Physicochemical and Conformational Properties 
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3.1 INTRODUCTION 
Our laboratory has previously investigated the pharmacokinetic properties of 
the opioid peptide DADLE (H-Tyr-D-Ala-Gly-Phe-D-Leu-OH) and the cyclic 
prodrugs of DADLE.1-12  These cyclic prodrugs displayed promising physicochemical 
properties that were expected to enhance cellular permeation.1-4  The cyclic prodrugs, 
however, did not exhibit improved in vitro cell permeation as expected,3,5 and recent 
studies also confirmed the poor permeation of the prodrugs in vivo.6  It was 
discovered that the poor permeability of the cyclic prodrugs is attributable to their 
substrate specificity for efflux transporters [e.g., P-glycoprotein (P-gp)].3,5,7,8  Since it 
has been established that many P-gp substrates are also substrates for phase I 
enzymes,9-12 the potential oxidative metabolism of these prodrugs became of interest.   
Based on the connection between substrate specificity of phase I enzymes and 
P-gp , the oxidative stability of the cyclic prodrugs was investigated.  As reported in 
the previous chapter, the cyclic peptide prodrug CA-DADLE undergoes rapid 
oxidative metabolism in the presence of liver microsomes and human recombinant 
cytochrome P450-3A4 (hCYP3A4).  The two main sites of oxidative metabolism on 
CA-DADLE were discovered to be located on the Tyr1 and Phe4 residues of the 
peptide.  Using this knowledge and our general understanding of opioid peptides, two 
new CA-DADLE analogs were designed (Figure 3.1).  This was accomplished 
through chemical modification of the amino acid sequence, creating the new cyclic 
prodrugs CA-[Cha4,D-Leu5]-Enk (1) and CA-[Cha4,D-Ala5]-Enk (2).  Ultimately, 
these prodrugs were designed in an attempt to improve metabolic stability and to  
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Figure 3.1. Structures of DADLE, CA-DADLE, and CA-DADLE analogs. 
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potentially enhance oral bioavailability.  In this chapter, the design, synthesis, 
physicochemical characterization, and solution conformation of the two CA-DADLE 
analogs will be discussed.   
 
 
3.2 MATERIALS AND METHODS 
3.2.1 Materials 
Lindlar’s catalysis was purchased from Fluka Chemical Corporation 
(Milwaukee, WI).  The amino acids were purchased from Novabiochem (La Jolla, 
CA), and the final coupling reagent, N-N-Bis(2-oxo-3-oxozolidinyl)-phosphinic 
chloride was purchased from TCI-America (Portland, OR).  Silica gel (Selecto 
Scientific) and solvents (HPLC grade) were purchased from Fisher Scientific 
(Pittsburgh, PA).  All other chemicals were purchased from Sigma-Aldrich (St. Louis, 
MO).  Tetrahydrofuran was distilled from sodium metal in the presence of 
benzophenone. Dichloromethane was distilled over calcium hydride.  All other 
chemicals and solvents were used as received.   
 
3.2.2 Synthesis 
Abbreviations: ACN, acetonitrile; Boc, t-butoxy carbonyl; Bop-Cl, bis(2-oxo-3-
oxazolidinyl) phosphinic chloride; CDCl3, chloroform-D; CH2Cl2, dichloromethane; 
DMAP, 4-dimethylamino pyridine; DMSO, dimethylsulfoxide; EDC-HCl, 1-(3-
dimethylaminoproply)-3-ethylcarbodiimide; HOBt, 1-hydroxybenzotriazole; LDA, 
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lithium diisopropylamide; MeOD, methanol-D4; MgSO4, magnesium sulfate; 
NHCO3, sodium biocarbonate; OAll, allyl protecting group; Pac, phenacyl protecting 
group; P-gp, P-glycoprotein; ROESY, rotating frame Overhauser effect spectroscopy; 
TEA, triethyl amine; TFA, trifluoracetic acid; THF, terahydrofuran; TOCSY, total 
correlation spectroscopy 
 
Standard solution-phase peptide synthesis using Boc-amino acid chemistry 
 
Coupling:  The Boc-protected amino acid (26 mmol) was dissolved in dry 
tetrahydrofuran (300 mL) and put on ice.  To this solution was added EDC-HCl (7 g, 
37 mmol) and HOBt (5.7 g, 42 mmol).  The solution was stirred for 5 min, and then 
to this solution was added TEA (5.6 g, 55 mmol), DMAP (353 mg, 3 mmol), and the 
C-terminal-protected peptide (30 mmol).  The reaction was stirred at room 
temperature for 5 hr.  The tetrahydrofuran was removed in vacuo.  The residue was 
dissolved in ethyl acetate (500 mL) and extracted with 10% citric acid (3 × 200 mL), 
5% NHCO3 solution (3 × 200 mL), and saturated brine (1 x 200 mL).  The organic 
layer was dried over MgSO4 and filtered.  The solvent was removed to give the 
desired peptide.  The product was used in the next step without purification.   
 
Deprotection:  To remove the N-terminal Boc group, the peptide (34.3 mmol) was 
dissolved in ethyl acetate (50 mL) and cooled to 0°C.  HCl gas was bubbled through 
the solution for 15 min.  The gas was removed, and the reaction was stirred an 
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additional 15 min at 0°C.  The solvent was removed in vacuo.  The product was used 
unpurified in the next reaction.   
 
Peptide arm: 
Boc-D-Ala-Gly-OAll (4).  Yield: 100 %.  Rf = 0.51  (chloroform/methanol, 3:1). 1H 
NMR (400 MHz, CDCl3) δ 1.28 (d, 3H, J=7.0), 1.34 (s, 9H), 3.96 (m, 2H), 4.21 (s, 
1H), 4.53 (d, 2H, J=5.6), 5.13 (d, 1H, J=10.4), 5.21 (d, 1H, J=17.2), 5.54 (s, 1H), 5.79 
(m, 1H).  13C NMR (400 MHz, CDCl3) δ 28.22, 41.08, 49.85, 79.67, 118.63, 124.85, 
128.73, 131.48, 143.25, 155.49, 169.4, 173.6.   
 
H-D-Ala-Gly-OAll (5).  Yield: 100%.  Rf  = 0.12  (dichloromethane/methanol/acetic 
acid, 20:3:0.1). 1H NMR (400 MHz, MeOD) δ 1.56 (d, 3H, J=5.8), 3.99 (m, 2H), 4.59 
(d, 2H, J=4.8), 5.18 (d, 1H, J=10.3), 5.27 (d, 1H, j=17.1), 5.89 (m, 1H).  13C NMR 
(400 MHz, CDCl3) δ 40.74, 49.03, 65.55, 117.58, 131.9, 169.29, 170.39.   
 
Boc-Tyr-D-Ala-Gly-OAll (6).  Yield: 100%.  Rf = 0.23  (chloroform/acetonitrile, 
3:1). 1H NMR (400 MHz, CDCl3) δ 1.20 (d, 3H, J=6.5), 1.37 (s, 9H), 2.91 (m, 2H), 
4.05 (dd, 2H, J1=17.4, J2=52.3), 4.16 (m, 1H), 4.33 (d, 1H, J=7.2), 4.61 (d, 2H, 
J=5.6), 5.21 (dd, 1H, J1=1.2, J2=10.5), 5.31 (dd, 1H, J1=1.5, J2=17.2), 5.93 (m, 1H),  
6.72 (d, 2H, J=8.5), 7.04 (d, 2H, J=8.3).  13C NMR (400 MHz, MeOD) δ 17.58, 
28.28, 41.27, 48.62, 56.64, 66.05, 80.32, 115.63, 118.94, 127.39, 130.32, 131.43, 
155.55, 155.85, 169.67, 172.06, 172.87.   
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Boc-Tyr-D-Ala-Gly-OH (7).  Yield: 100%.  Rf= 0.11  (chloroform/methanol, 3:1). 
1H NMR (400 MHz, MeOD) δ 1.21 (t, 3H J1= 7.0, J2=14.1) 1.10 (s, 9H), 2.92 (m, 
2H), 3.69 (dd, 2H, J1=17.1, J2=76.0), 4.21 (s, 1H), 4.31 (m, 1H), 6.72 (d, 2H, J=7.7), 
7.05 (d, 2H, J=7.7).  13C NMR (400 MHz, MeOD) δ 17.01, 27.37,36.88,42.55,56.95, 
79.46,114.86,127.44, 130.02, 155.99, 156.42, 173.21, 173.45.   
 
Boc-Tyr-D-Ala-Gly-Cha-OAll (8).  Yield: 100%.  Rf= 0.78  (chloroform/methanol, 
3:1). 1H NMR (400 MHz, MeOD) 0.91 (m, 2H), 1.25 (m, 6H), 1.41 (s, 9H), 1.71 (m, 
7H), 2.90 (m, 2H). 3.90 (m 2H), 4.14 (m, 1H), 4.52 (m, 1H0, 4.61(m, 2H), 5.31 (dd, 
2H, J1=1.4, J2=17.2), 5.91 (m, 1H),6.72 (d, 2H J=8.3), 7.03 (d, 2H, J=8.2).  13C NMR 
(400 MHz, MeOD) δ15.72, 25.72, 25.97, 26.17, 27.42, 31.86, 33.35, 33.79, 38.62, 
42.02, 49.48, 50.20, 56.91, 65.28, 79.45, 114.83, 117.29, 127.37, 130.02, 131.96, 
156.01, 156.54, 170.22, 172.27, 173.27, 173.94.   
 
H-Tyr-D-Ala-Gly-Cha-OAll (9).  Yield: 100%.  Rf= 0.68  (chloroform/methanol, 
3:1). 1H NMR (400 MHz, MeOD) δ 0.95 (m, 2H), 1.25 (d, 3H, J=7.2), 1.40 (m, 1H), 
1.70 (m, 7H), 3.07 (m, 2H), 3.91 (s, 2H), 4.10 (t, 1H, J1=7.5, J2=15.0), 4.25 (d, 1H, 
J=7.2), 4.55 (dd, 1H, J1=6.5, J2=8.4), 4.62 (s, 2H), 5.23 (d, 1H J=10.5), 5.31 (d, 1H, 
J=17.2), 5.92 (m, 1H), 6.80 (d, 2H J=8.3), 7.11 (d, 2H J=8.3).  13C NMR (400 MHz, 
MeOD) δ16.04, 25.72, 25.93, 26.13, 31.89, 33.29, 33.88, 36.28, 38.74, 41.81, 49.58, 
50.10, 54.80, 65.47, 115.38, 117.43, 124.69, 130.22, 131.86, 156.88, 168.73, 170.07, 
170.15, 172.67, 173.56. 
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CA-Linker: 
Phenacyl 3-(2-hydroxyphenyl)-propynoate (10).   Compound 10 was synthesized 
using a method previously described.2  1H NMR (400 MHz, CDCl3) δ 5.52 (s,2H), 
6.93 (t, 1H, J1=7.5, J2=16.1), 7.00 (d, 1H, J=8.4), 7.39 (t, 1H, J1=8.3, J2=17.4), 7.49 
(m, 3H), 7.64 (t, 1H, J1=7.4, J2=13.7), 7.94 (d, 2H, J=9.5).  13C NMR (400 MHz, 
CDCl3) δ 67.18, 83.69, 83.33, 105.84, 115.96, 120.69, 127.87, 128.99, 133.38, 
133.75, 133.83, 134.22, 153.14, 159.07, 191.02.    
 
Phenacyl 3-(2'-Boc-alacylocyl hydroxyphenyl)-propynoate (11).  Phenacyl 3-(2-
hydroxylphenyl)-propynoate (10) (1g, 3.7 mmol) was dissolved in 40 mL of dry 
dichloromethane.  In another flask containing 10 mL of dry dichloromethane was 
dissolved Boc-D-Ala-OH (840 mg, 4.4 mmol), EDC (707 mg, 3.7 mmol), and DMAP 
(452 mg, 3.7 mmol).  The mixture was stirred at 0°C for 5 min.  The solution with 
compound 10 was transferred to the flask containing the activated amino acid via 
cannula and stirred at 0°C for 5 hr.  Dichloromethane was removed in vacuo.  The 
residue was dissolved in ethyl acetate (200 mL) and extracted with 10% citric acid (3 
× 100 mL), 5% NaHCO3 solution (3 × 100 mL), and brine (1 × 100 mL).  The organic 
layer was dried over MgSO4, filtered, and evaporated to a foam (1.05 g, 66%).  The 
foam was purified by silica gel column chromatography with chloroform/ethyl acetate 
(20:1) to give a yellowish oil (750 mg, 47%).  Rf = 0.37 (chloroform/ ethyl acetate, 
20:1).  1H NMR (400 MHz, CDCl3) δ 1.46 (s, 9H), 1.68 (d, 3H, J=7.28), 4.64 (m, 
1H), 5.31 (m, 1H), 5.48 (s, 2H),  13C NMR (400 MHz, CDCl3) δ 17.99, 28.29, 49.56, 
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67.15, 79.82, 82.52, 84.48, 85.20, 113.51, 122.75, 126.32, 127.77, 128.92, 132.41, 
133.77, 134.26, 152.78, 155.36, 171.29, 190.76.   
 
Phenacyl 3-(2'-Boc-alacylocyl hydroxyphenyl)-propenoate (12).  Phenacyl 3-(2'-
Boc-alacylocyl hydroxyphenyl)-propynoate (11) (750 mg, 1.72 mmol) was dissolved 
in absolute ethanol (60 mL).  To this was added Lindlar catalyst (5 wt % of palladium 
on calcium carbonate, poisoned with lead; 10% w/w, 75 mg) and quinoline (2% w/w, 
15 mg).  The reaction was stirred at 0°C.  Hydrogen gas was bubbled through the 
solution for 30 min.  The HCl gas was removed and the reaction, which was 
monitored by 1H NMR, was stirred under a hydrogen atmosphere until complete.  
Upon completion, the catalyst was removed and the solvent evaporated in vacuo to 
give a yellowish foam (680 mg, 82%).  The foam was purified by silica gel column 
chromatography with hexanes/ethyl acetate (4:1) to give a light yellow solid (670 mg, 
80%).  Rf =0.65 (ethyl acetate/hexanes/methanol, 2:4:1).  1H NMR (400 MHz, 
CDCl3) δ 1.46 (s, 9H), 1.56 (d, 3H, J=7.3), 4.53 (t, 1H, J1=7.2, J2=14.5), 5.37 (d, 2H, 
J=16.4), 6.22 (d, 1H, J=12.2), 7.08 (m, 2H), 7.21 (t, 1H, J1=7.6, J2=15.2), 7.32 (m, 
1H), 7.46 (m, 2H), 7.59 (m, 2H), 7.87 (d, 2H, J=7.2).  13C NMR (400 MHz, CDCl3) δ 
18.35, 28.34, 49.56, 66.09, 79.96, 121.21, 121.74, 125.73, 127.80, 128.83, 129.93, 
130.30, 133.92, 134.09, 139.60, 147.86, 155.38, 164.52, 171.62, 192.09.   
 
3-(2'-Boc-alacylocyl hydroxyphenyl)-propenoic (13).  A mixture of phenacyl 3-(2'-
Boc-alacylocyl hydroxyphenyl)-propenoate (12) (100 mg, 0.21 mmol) and zinc 
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powder (271 mg, 4.14 mmol) was cooled to 10°C.  Acetic acid (22 mL) was slowly 
added to the reaction.  The mixture was stirred at 10°C for 30 min.  The supernant 
was filtered and concentrated in vacuo.  The residual oil was purified by silica gel 
column chromatography with ethyl acetate/hexanes/methanol (2:4:1) to give a 
colorless oil (90 mg, 75%).  Rf = 0.43 (ethyl acetate/hexanes/methanol (2:4:1).  1H 
NMR (400 MHz, MeOD) δ 1.48 (s, 9H), 1.52 (d, 3H, J=7.3), 4.38 (m, 1H), 6.10 (d, 
1H, J=12.4), 6.87 (d, 1H, J=12.4), 7.11 (d, 1H, J=8.0), 7.22 (t, 1H, J1=7.4, J2=14.6), 
7.35 (t, 1H, J1=7.6, J2=15.2), 7.64 (d, 1H, J=7.3).  13C NMR (400 MHz, CDCl3) δ 
18.07, 28.30, 49.43, 80.25, 121.72, 122.81, 125.78, 128.16, 129.80, 130.47, 137.88.   
 
Compound (14).  A mixture of compound 13 (112 mg, 0.31 mmol), EDC (82 mg, 
0.43 mmol), and HOBt (66 mg, 0.49 mmol) was dissolved in dry tetrahydrofuran (6 
mL) and stirred at 0°C for 5 min.  To this solution was added DMAP (4 mg, 0.03 
mmol) and TEA (66 mg, 0.64 mmol).  In another flask, H-Tyr-D-Ala-Gly-Cha-OAll 
(9) (170mg, 0.33 mmol) was dissolved in 4 mL dry tetrahydrofuran and transferred 
via cannula to the reaction flask containing compound 13.  The mixture was stirred at 
room temperature for 6 hr.  Tetrahydrofuran was removed in vacuo.  The residue was 
dissolved in ethyl acetate (100 mL) and extracted with 10% citric acid (2 × 50mL), 
5% NaHCO3 solution (2 × 50 mL), and brine (1 × 500 mL).  The organic layer was 
dried over MgSO4, filtered, and evaporated to a yellowish white solid (200 mg, 80%).  
The solid was purified by silica gel column chromatography with 
chloroform/methanol (20:1) to give a white solid (110 mg, 44%). Rf = 0.26 
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(chloroform/methanol, 20:1).  1H NMR (400 MHz, CDCl3) δ 0.87 (m, 2H), 1.16 (m, 
6H), 1.40 (s, 9H), 1.53 (d, 3H, J=7.2), 1.63 (m, 7H), 2.55 (m, 1H), 2.74 (m, 1H), 3.90 
(m, 2H), 4.35 (m, 2H), 4.59 (m, 3H), 5.24 (d, 2H, J=10.4), 5.33 (d, 2H, J=17.3), 5.85 
(m, 1H), 6.10 (d, 1H J=12.1), 6.67 (m, 3H), 6.84 (d, 2H, J=7.3), 7.00 (m, 2H), 7.20 
(m, 1H), 7.32 (m, 1H).  13C NMR (400 MHz, CDCl3) δ 18.11, 25.91, 26.10, 26.36, 
28.37, 32.32, 33.40,33.92, 39.40,49.33, 50.35, 65.85, 80.33, 115.65, 118.70, 121.88, 
126.52, 127.15, 129.01, 130.28, 131.61, 147.80, 155.51, 166.84, 169.65, 172.59, 
173.01.   
 
Compound (15) 
Removal of Allyl group:  Compound 14 (110 mg, 0.13 mmol) was dissolved in 10 
mL dry tetrahydrofuran.  To this solution was added Pd(PPh3)4 (15.5 mg, 1.0 mmol) 
and morpholine (117 mg, 1.34 mmol).  The reaction was then stirred at room 
temperature for 90 min.  The tetrahydrofuran was evaporated in vacuo and the 
residual oil was purified by silica gel column chromatography with 
chloroform/methanol (3:1).  Rf = 0.43 (chloroform/methanol, 3:1).   
 
Removal of Boc-group:  The -OAll deprotected product from above was dissolved in 
ethyl acetate (60 mL) and cooled to 0°C.  HCl (gas) was bubbled through the solution 
for 10 min.  The HCl gas was removed, and the solution stirred for another 10 min at 
0°C.  The ethyl acetate was evaporated to give a white solid in quantitative yield.  The 
product was used in the next step without further purification.  Total yield for these 
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two steps was 49%.  Rf = 0.47 (chloroform/methanol, 20:1).  1H NMR (400 MHz, 
MeOD) δ 0.94 (m, 2H), 1.17 (d, 3H, J=7.3), 1.43 (m, 1H), 1.57 (m, 1H), 1.72 (d, 3H, 
J= 7.1), 1.76 (m, 7H), 2.87 (d, 2H, J=7.5), 3.66 (dd, 2H, J1=16.8, J2=50.6), 3.86 (m, 
1H), 4.30 (m, 1H), 4.40 (m, 2H), 6.25 (d, 1H, J=12.1), 6.72 (d, 2H, J=8.3), 6.83 (d, 
1H, J=12.2), 7.01 (d, 2H, J=8.1), 7.17 (d, 1H, J=8.5), 7.23 (t, 1H, J1=7.3, J2= 14.7), 
7.38 (d, 2H, J=7.4).  13C NMR (400 MHz, MeOD) δ 19.38, 25.70, 25.97, 26.18, 
31.83, 33.43, 33.81, 36.17, 38.92, 42.06, 48.66, 56.10, 60.15, 114.87, 121.33, 125.53, 
126.13, 126.85, 129.05, 129.15, 129.91, 130.13, 133.25, 147.13, 156.12, 166.79, 
168.31, 170.40, 172.70.   
 
CA-[Cha4,D-Ala5]-Enk (2).  Compound 15 was dissolved in 1 mL anhydrous N,N-
dimethylformamide and then diluted with 50 mL of dichloromethane.  To this 
solution was added TEA (30 mg, 0.3 mmol) and Bop-Cl (53 mg, 0.21 mmol).  A 
cloudy mixture resulted, and the reaction was stirred at room temperature for 18 hr.  
The resultant clear yellow solution was evaporated in vacuo to give a yellow solid.  
The solid was dissolved in ethyl acetate (10 mL) and washed with another 10 mL of 
water.  The ethyl acetate layer was collected and washed with 10% citric acid (1 × 10 
mL), and 5% NaHCO3 solution (1 × 10mL). The organic layer was collected, dried 
with MgSO4, filtered, and evaporated to a clear oil.  The oil was purified by semi-
preparative HPLC with UV detection.  The elulate was analyzed by ESI-MS.  
Fractions containing peptide prodrug were combined and lyophilized to give a white 
solid (6.7 mg, 34%).  Semi-preparative HPLC was done using a C18 Dynamax 
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column (300 Ǻ).  The cyclic peptide prodrug was isolated using a gradient from 10% 
to 100% B (solvent A: 90% water with 0.01% formic acid; solvent B: 90% 
acetonitrile with 0.01% formic acid).  The gradient was applied stepwise for a total 
run time of 121 min with a flow rate of 5 mL/min (16 min gradient from 10% to 30% 
B; 10 min gradient from 30% to 40% B; 40% B for 10 min; 15 min gradient from 
40% to 45% B; 10 min gradient from 45% to 100% B; 15 min at 100% B; 15 min 
return to 10% B; 30 min equilibration at 10% B).  The peptide prodrug had a 
retention time of about 45 min. Rf = 0.22  (chloroform/methanol, 20:1) 1H NMR (400 
MHz, MeOD) δ 0.99 (m, 4H), 1.20 (d, 3H, J=7.3), 1.25 (m, 9H), 1.56 (d, 3H, J=7.4), 
1.74 (m, 7H), 2.85 (m, 2H), 3.88 (m, 2H), 4.03 (m, 1H), 4.28 (m, 1H), 4.46 (m, 1H), 
4.65 (m, 1H), 6.20 (d, 1H, J=12.1), 6.70 (d, 2H, J=8.5), 6.78 (d, 1H, J=12.0), 6.97 (d, 
2H, J=8.3), 7.07 (m, 1H), 7.23 (m, 1H), 7.36 (m, 2H). ESI-MS m/z 662.6 (M+1) 
 
CA-[Cha4,D-Leu5]-Enk (1). 1H-NMR (500 MHz, MeOD-d4) δ 1.37 (dd, 6H, J1=6.0, 
J2=17.3), 1.57 (d, 3H, J=7.3), 1.65 (m, 3H), 1.82 (m, 2H), 2.11 (m, 9H), 3.10 (dd, 1H, 
J1=7.3, J2=13.7), 3.21 (m, 1H), 4.18 (d, 1H, J=17.1), 4.31 (dd, 1H, J1=7.3, J2=14.6) 
4.68 (t, 1H, J1=7.7, J2=15.1), 4.86 (dd, 1H, J1=5.5, J2=10.0), 5.05 (m, 1H), 6.55 (d, 
1H, J=12.1), 7.06 (d, 2H, 8.5), 7.14 (d, 1H, J=12.1), 7.28 (d, 2H, J=8.4), 7.42 (d, 1H, 
J=8.0), 7.60 (m, 2H), 7.73 (m, 1H). ESI-MS m/z 704.5 (M+1).   
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3.2.3 Physicochemical Properties 
The molecular surface area and cLogP estimations were performed on a 
Silicon Graphics Computer using Sybyl Version 7.2.3 (Tripos Inc., St. Louis, MO).  
Calculations were performed on a final energy-minimized form of the cyclic prodrugs 
1 and 2.  The cLogP values were obtained from the Molecular Spreadsheet.  The 
molecular surface areas were calculated using Connolly molecular surfaces.   
 
3.2.4 Conformation 
The solution conformations of cyclic prodrugs 1 and 2 were determined by 
NMR and molecular dynamics (MD) simulations.  The NMR data were collected 
using 2-3 mg of the cyclic prodrugs dissolved in DMSO-d6 (0.6 mL).  One- and two-
dimensional NMR experiments were performed on a Varian Inova 800 at 293 K.  
Coupling constants were obtained from a DQF-COSY spectrum at 293 K.  ROESY 
spectra were collected with a 300 ms spin-lock time.  The through space inter-proton 
interactions were calculated using the volume integration of the ROE amide cross-
peaks.  The intensities of the interactions were classified as strong, medium, or weak 
using the upper and lower boundary distances of 1.8-2.8, 1.8-3.6, and 1.8-5 Ǻ, 
respectively.  The NMR data were processed using FELIX software (version 95, 
Biosym Technologies, San Diego, CA) with a final matrix of 1K x 1K data points.   
The solution structures of cyclic prodrugs 1 and 2 were also evaluated using 
MD simulations.  Because of the highly restricted nature of the cyclic prodrugs (i.e., 
the conformationally restricting cis-alkene and trans peptide bonds), the MD 
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simulations were determined starting from an energy minimized cyclic structure 
generated in Sybyl (Version 7.2.3; Tripos Inc., St. Louis, MO).  From this energy 
minimized structure, a single peptide bond between the linker moiety and the fifth 
amino acid was broken to give a linear precursor.  This linear precursor was energy 
minimized using the following constraints:  (i) the cis-alkene moiety was held to a cis 
conformation and (ii) all the bonds in the peptide backbone were held in the trans 
conformation.  MD simulations using the ROE constraints from the 2D NMR data 
(see above) were then performed to slowly bring the two ends of the linear precursor 
together.  The MD simulations were performed stepwise in 5 simulations at 300 K for 
5 ps each.  The starting bond closure distance between the ends of the linear precursor 
was 5 Ǻ.  A starting penalty force of 25 kcal/mol Ǻ2 was used for both the closing of 
the terminal ends of the linear precursor, and the ROE constraint distances within the 
backbone.  During each subsequent MD simulation step, the bond closure distance 
was decreased to 3, 2, and 1.7Ǻ, and the penalty force constant was doubled.  Once 
the ends of the linear precursor were within 1.7-2.0 Ǻ, a covalent bond was made 
joining the two ends.  A final MD simulation using only the ROE constraints with the 
maximum penalty force constant was performed.  This gave the final cyclic prodrug 
structure.  The dielectric constant was used to simulate solvent effects.  Dielectric 
constants of 45 and 87.74 were used to represent DMSO and water, respectively.  The 
final cyclic prodrug structures were analyzed in terms of dihedral angles and observed 
ROE distances.   
 
 83
3.3 RESULTS 
3.3.1 Synthesis 
The synthesis and characterization of the new CA-DADLE analogs (Figure 
3.1) was undertaken using methodology described earlier by our labortary.2  
Generally, the cyclic prodrugs were synthesized by cyclization of a linear precursor, 
forming the peptide bond between the fourth and fifth amino acids in the peptide 
sequence (Figure 3.2).  These linear precursors were built from a linker moiety and a 
tetrapeptide (Figure 3.2).  The general synthesis of the linker moiety was reported 
elsewhere.13  The tetrapeptides were synthesized utilizing standard solution phase 
Boc-amino acid chemistry with L-amino acids unless otherwise designated.  The 
structural identities of the cyclic prodrugs were confirmed by 1H-NMR and ESI-MS.   
 
3.3.2 Physicochemical Properties 
Cyclic peptide prodrugs 1 and 2 were designed to have permeation-favorable 
physicochemical properties and, thus, optimized cell membrane permeability.  
Lipophilicity and molecular size are two important physicochemical properties that 
directly affect cell membrane permeation.14-16  cLogP values give a good estimate of a 
molecule’s lipophilicity, and the calculated molecular surface area gives a good 
estimate of the overall size of the molecule.  For these reasons, the molecular surface 
area and cLog P values were determined for CA-[Cha4,D-Leu5]-Enk (1) and CA-
[Cha4,D-Ala5]-Enk (2).  The cyclic prodrug analogs 1 and 2 exhibited cLogP values 
of 6.19 and 4.73, respectively (Table 3.1).  These results illustrate that the cyclic 
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Figure 3.2.  Retrosynthetic analysis leading to the peptide arm and coumarinic acid 
linker fragments. 
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Table 3.1. Physicochemical properties of DADLE and its cyclic peptide prodrugs. 
 
 
 Molecular 
mass 
 
cLogP 
Molecular surface 
area (A2)a 
DADLE 571 -0.32 529.89 
CA-DADLE 697 4.96 548.50 
CA-[Cha4,D-Leu5]-Enk 703 6.19 536.99 
CA-[Cha4,D-Ala5]-Enk 661 4.73 474.34 
a
MOLCAD of SYBL 7.2.3 was used to calculate the Connolly molecular surface. 
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peptide prodrugs (1 and 2) display higher cLogP values than does DADLE (cLogP = 
-0.32; Table 3.1).  This verifies the increased lipophilic character of cyclic prodrugs 1 
and 2 compared to DADLE.   
Along with lipophilicity, molecular surface area is another important 
physicochemical property to consider when characterizing a molecule.  With the 
addition of a linker moiety, the cyclic prodrugs have a higher molecular weight than 
DADLE (Table 3.1).  Despite this fact, the cyclic prodrugs were found to have 
molecular surface areas similar to DADLE (Table 3.1).  This confirms the idea that 
when linear, the peptides are conformationally mobile.  Once cyclized, however, they 
adopt a more compact structure.  Having a defined solution structure could play a role 
in the cellular membrane permeability of cyclic prodrugs 1 and 2.  
 
3.3.3 Conformation 
2D NMR studies were conducted to elucidate the solution conformation of 
CA-[Cha4,D-Leu5]-Enk (1) and CA-[Cha4,D-Ala5]-Enk (2).  Proton chemical shifts 
were identified from total correlation spectroscopy (TOCSY) and rotating frame 
Overhauser effect spectroscopy (ROESY).  Characterization of the peptide backbone 
conformation and intramolecular hydrogen bonding of the cyclic prodrug was 
determined using amide-amide peak correlations in the ROESY spectrum.  CA-
[Cha4,D-Leu5]-Enk (1) shows through-space interactions between the NH of Gly3 and 
the NH of cychexalanine4 (Cha) and also between the NH of Cha4 and the NH of Leu5 
(Figure 3.3; Panel A).  The same ROE cross-peaks are observed in CA-[Cha4,D- 
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Figure 3.3.  Amide region of the ROESY spectrum for cyclic CA-DADLE analogs; 
CA-[Cha4,D-Leu5]-Enk (Panel A) and CA-[Cha4,D-Ala5]-Enk (Panel B). 
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Ala5]-Enk (2) (Figure 3.3; Panel B).  In the spectrum of CA-[Cha4,D-Ala5]-Enk (2), 
these two peaks are resolved, but they overlap in the CA-[Cha4,D-Leu5]-Enk (1) 
spectrum.  This overlap in the cyclic prodrug 1 spectrum makes the strength of the 
connectivity and, thus, the through space inter-proton interactions difficult to 
determine exactly.  Therefore, the NMR distance constraints determined for CA-
[Cha4,D-Leu5]-Enk (1) are more variable than for CA-[Cha4,D-Ala5]-Enk (2). The 
data clearly indicate, however, that the two cyclic analogs 1 and 2 both show ROE 
cross-peaks indicative of a β-turn structure.   
The solution conformations of cyclic prodrugs 1 and 2 were additionally 
characterized by MD simulations.  The simulations were performed using distance 
constraints obtained from the ROESY spectra (see above) with the energy-minimized 
average structures shown in Figure 3.4 (Panels A and B).  The measured dihedral 
angles (φ,ψ) were all within 36° of the dihedral angles calculated from the NMR-
derived coupling constant with two exceptions (Table 3.2). These deviations occurred 
with CA-[Cha4,D-Leu5]-Enk (1), where the phi angle (φ) related to Gly3 solvated in 
water was measured to be slightly higher than the NMR calculated values.  Also, the 
phi (φ) and psi (ψ) dihedral angles related to Gly3and Cha4 in cyclic prodrug 1 were  
found to be higher than expected.  These derivations most likely resulted from 
applying the estimated NMR distance constraints related to Gly3 and Cha4 in the MD 
simulations.  The simulations were further validated using through-space 
intramolecular ROE distance constraints.  In the MD-derived models, the measured 
distances from the NH of the peptide backbone to the Hα of the amino acid side chain 
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were found to correlate well with the NMR-derived distance constraints.  In these 
experiments, solvation was mimicked by changes in the dielectric constant.  Varying 
the dielectric constant in the MD simulations was found to have very little effect on 
the measured dihedral angles (Table 3.2) and, ultimately, the final energy-minimized 
structure of cyclic prodrugs 1 and 2 (Figure 3.4, Panel C).   
 
 
3.4 DISCUSSION 
In an attempt to improve the biopharmaceutical properties of cyclic DADLE 
prodrugs, two new analogs of CA-DADLE, CA-[Cha4,D-Leu5]-Enk (1) and CA-
[Cha4,D-Ala5]-Enk (2), were synthesized and their physicochemical properties 
characterized (Figure 3.1).  The main goal in designing these new CA-DADLE 
analogs was to add stability toward oxidative metabolism while still maintaining high 
affinity for the opioid receptor.  Previous studies from our laboratory illustrated that 
CA-DADLE was oxidized on the Tyr1 and Phe4 residues (Chapter 1).  Since it has 
been well established that modification to the Tyr1 residue of an opioid peptide 
dramatically decreases opioid receptor affinity,17-20 changes at this site were not 
attempted.  We decided instead to modify the Phe4 residue of CA-DADLE.   
The cyclic prodrug analog 1 was designed to differ from CA-DADLE at a 
selected metabolically labile amino acid.  A modification of the fourth amino acid 
residue from Phe to Cha created CA-[Cha4,D-Leu5]-Enk (1).  In the enkephalin class 
of opioid peptides, peptides with this structural change (Phe to Cha) have been shown 
 90
 
  A                                                                     B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                      C 
 
 
Figure 3.4.  Energy-minimized average structures of CA-[Cha4,D-Leu5]-Enk (1) 
(Panel A) and CA-[Cha4,D-Leu5]-Enk (2) (Panel B) with intramolecular hydrogen 
bonds shown (- -- - - ).  CA-DADLE analogs overlaid, capped stick = CA-[Cha4,D-
Leu5]-Enk (Panel C).   
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Table 3.2. Chemical shifts, coupling constants, and dihedral angles (calculated from 
coupling constants and measured from energy-minimized average structures) for CA-
DADLE analogs. 
 
 
Measured  Chemical 
shift 
(ppm) NH 
Coupling 
constant 
3JNHα (Hz) 
 
calcd φ (deg) φ 
(deg) 
DMSO 
φ 
(deg) 
water 
ψ 
(deg) 
DMSO 
ψ 
(deg) 
water 
                   CA-[Cha4,D-Leu5]-Enk 
Tyr-1 8.10 3.9 -179, -65, 8, 104 -41 -40 -47 -48 
D-Ala-2 8.50 4.6 -175, -70, 19, 102 -150 -156 -62 -59 
Gly-3* 7.91 9.0 -149, -43, 43, 149 -164 -193 57 55 
Cha-4 7.29 3.0 -172, -112, 12, 60 -136 -138 -65 -69 
D-Leu-5 7.89 3.4 -175, -115, 15, 54 -149 -149 NA NA 
        
                   CA-[Cha4,D-Ala5]-Enk 
Tyr-1 8.11 3.6 -178, -65, 7, 106 -48 -54 -48 -54 
D-Ala-2 8.51 4.6 -175, -70, 19, 102 -170 -164 -50 -60 
Gly-3* 7.93 9.1 -148, -43, 43, 148 -162 -150 57 47 
Cha-4 7.25 3.0 -172, -112, 12, 60 -136 -136 32 41 
D-Ala-5 7.90 3.6 -119, -12, 58, 180 56 48 NA NA 
* ΣJNH-CH2.   
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to retain opioid-like activity in vivo21 with only slight modification of the potency and 
binding affinity of the peptide.22  Other opioid peptides have also been shown to 
maintain modest binding affinity to the opioid receptors with a Phe to Cha 
modification in the amino acid sequence.23-25   
The second analog, CA-[Cha4,D-Ala5]-Enk (2), contains the aforementioned 
Phe4-to-Cha4 structural change with an additional modification at the fifth amino acid 
residue.  The rationale for changing this amino acid from D-Leu5 to D-Ala5 was to 
increase the bioconversion of the prodrugs.  The bioconversion is catalyzed by 
esterases and is thought to proceed first through hydrolysis of the ester bond (Figure 
3.5).  Cleavage of this bond leaves a phenolic group on the aromatic linker moiety 
and releases the C-terminal end of the peptide, forming an intermediate.  Finally, 
intramolecular lactonization results in the formation of coumarin and the linear 
peptide.  Since hydrolysis of the ester bond is the rate-determining step in the 
bioconversion, a quick cleavage of this bond would be preferred.  The new cyclic 
prodrug analog 2 reduces steric bulk around the ester bond, leaving it more exposed 
to esterases and potentially aiding in the bioconversion of the cyclic prodrug.  In  
support of this idea, it has been shown that a decrease in steric bulk around the ester 
bond increases the lactonization rate in similar cyclic prodrugs.26   
The strategy for the synthesis was taken from a retrosythetic analysis of the 
desired molecules.  Retrosythethically, the bond between the fourth and fifth amino 
acid was broken, leading to a linear precursor (Figure 3.2).  The molecule was than 
further broken down into two parts: (i) a tetrapeptide arm and (ii) a linker moiety 
 93
 
 
 
 
 
 
 
 
 
 
Figure 3.5.  Scheme for the bioconversion of the ester-based cyclic prodrugs.   
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containing the fifth amino acid (Figure 3.2).  These two parts were the building 
blocks for the convergent synthesis of the cyclic peptide prodrug analogs.  The 
advantage to using this method is that all the cyclic prodrugs can be constructed from 
these two building blocks.  Thus, this strategy provides a reduction in the amount of 
synthesis required to make the cyclic prodrugs.   
Upon completion of the synthesis, the physicochemical properties of the new 
prodrugs CA-[Cha4,D-Leu5]-Enk (1) and CA-[Cha4,D-Ala5]-Enk (2) were 
determined.  The addition of the lipophilic linker and removal of charge by 
cyclization generated molecules that were more lipophilic than DADLE (Table 3.1).  
It was found that the addition of the linker to the cyclic prodrugs increased the 
molecular surface area of CA-[Cha4,D-Leu5]-Enk (1) only slightly and actually 
slightly decreased the molecular surface area of CA-[Cha4,D-Ala5]-Enk (2) compared 
to DADLE (Table 3.1).  Since an overall increase in the molecular surface area of a 
molecule typically leads to a decrease in cell membrane permeation,12,27,28 having 
cyclic molecules with molecular surface area similar to that of linear DADLE is 
advantageous to increasing their cell membrane permeation.  The results indicate that 
cyclic prodrug analogs 1 and 2 have no charge, are more lipophilic, and have a 
molecular surface area similar to that of DADLE, all of which will presumably lead 
to increased cell membrane permeation.   
Solution conformation is another important key to understanding the 
physicochemical properties and permeation of the cyclic prodrugs.  NMR and 
molecular modeling experiments were performed to probe the solution conformation 
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of cyclic prodrugs 1 and 2.  The cyclic structures were found to contain 
intramolecular hydrogen bonding not present in linear DADLE.  These interactions 
lead to a solution structure that is more defined in the cyclic prodrug analogs 1 and 2.  
Restricted conformations in cyclic DADLE prodrugs have been shown to alter the 
hydrogen-bonding potential and, therefore, change the physicochemical properties of 
the cyclic prodrugs.29-31  For cyclic prodrugs 1 and 2, the intramolecular hydrogen 
bonding is easily seen in the NMR spectra (Figure 3.3) and the MD models (Figure 
3.4; Panels A and B).  The ROE cross-peaks for both CA-[Cha4,D-Leu5]-Enk (1) and 
CA-[Cha4,D-Ala5]-Enk (2) (Figure 3.3) suggest a type I β-turn at D-Ala2-Gly3-Cha4-
Ala/Leu5 (Figure 3.6; Panel A).32  Evidence of the type I β-turn structure is seen 
between the same positions on the peptide regardless of the amino acid residues 
present.  This suggests that modification of the amino acid in the fifth position of the 
peptide leads to minimal differences in the conformational structure between the 
analogs.  An overlap of the MD models confirms the structural similarities between 
cyclic prodrugs 1 and 2 (Figure 3.4; Panel C).   
While both cyclic prodrugs 1 and 2 exhibit evidence of a type I β-turn 
structure at D-Ala2-Gly3-Cha4-Ala/Leu5 (Figure 3.6), the spectra also contains a third 
interaction between Ala2 and Gly3 (Figure 3.3).  Addition of this third cross-peak 
illustrates possible distortion away from the type I β-turn geometry.  Similar cyclic 
prodrugs have displayed this connectivity between the second and third amino acid 
residues and were shown to contain a type II β-turn structure (Figure 3.6; Panel 
B).29,30  The cyclic prodrug analogs 1 and 2 show this third cross-peak to be weaker 
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Figure 3.6.  Schematic representation of ROE cross-peaks indicative of β-turn 
structures, type I (Panel A) and type II (Panel B).   
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than the first two cross-peaks listed (Figure 3.3).  This indicates that both β-turn 
structures, type I and type II, coexist in solution.32  Since the first group of cross-
peaks is more intense, the type I β-turn is most likely the dominant structural feature 
in cyclic prodrug analogs 1 and 2.  One should also note that the residues of the β-
turn in both cyclic prodrugs 1 and 2 exhibit low coupling constants (~3-4 Hz, Table 
3.2).  This is typically indicative of a well-defined secondary structure and suggests 
that cyclic prodrugs 1 and 2 are locked into a single conformation.32  Overall, the data 
defining the solution conformation of the cyclic prodrugs suggests the following: (i) 
cyclic prodrugs 1 and 2 exhibit  rigid solution structures with a defined type I β-turn, 
(ii) this β-turn structure is slightly distorted from standard β-turn geometry, (iii) MD 
simulations show the solution structure of cyclic prodrug analogs 1 and 2 to be 
comparable, and  (iv) the NMR data illustrate a decreased hydrogen-bonding potential 
compared to DADLE for both cyclic prodrugs 1 and 2.  The solution conformation 
results and the favorable physicochemical properties indicate the likelihood of 
enhanced cellular membrane permeation by cyclic prodrugs 1 and 2.   
 
 
3.5 CONCLUSION 
We have successfully designed, synthesized, and characterized CA-[Cha4,D-
Leu5]-Enk (1) and CA-[Cha4,D-Ala5]-Enk (2), two new analogs of CA-DADLE.  In 
order to create analogs that potentially have reduced cytrochrome P450 metabolism, 
the amino acid sequence of the cyclic prodrugs was modified.  The synthesis involved 
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a convergent method where a linker moiety was combined with a peptide and then 
cyclized in a final step, forming the cyclic prodrugs.  The characterization of the 
cyclic prodrugs illustrates that they are uncharged, lipophilic, and have reduced 
hydrogen-bonding potential.  Given that cytochrome P450 and P-gp substrates have 
similar structure-activity relationships,9-12 it stands to reason that these modified 
prodrugs may also have reduced affinity for efflux transporters and, thereby, 
enhanced cell membrane permeation compared to CA-DADLE.  The data suggest that 
the CA-DADLE analogs have physicochemical properties favorable to increased cell 
membrane permeability.  Additional studies will be undertaken to test the metabolic 
stability and permeation of these cyclic prodrugs as well as their affinity toward 
efflux transporters.   
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Chapter 4 
 
Biopharmaceutical Properties of CA-DADLE Analogs 
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4.1 INTRODUCTION 
The biopharmaceutical properties of drugs have recently become a central 
focus in the drug development pipeline.1-3  Companies are now looking at these 
“drugable” properties earlier in the discovery process with the hope of cutting down 
on the cost and time associated with bringing a drug to market.2,4  Gone are the days 
when the discovery scientists knew little to nothing about the development of drug 
candidates beyond the benchtop.  A more complete pharmaceutical profile of a 
developing drug is now being considered at the discovery stage to cut back on the 
advancement of drug candidates that are great high affinity ligands in binding assays 
but are poor drugs.5  One way to go about this is to preliminarily sort drug candidates 
into “bins” in relation to their pharmaceutical properties.4,5  These bins classify the 
drugs into low, medium, and high range.  The more medium-to-high bins a drug 
candidate fits into, the more likely that molecule is to have favorable drug-like 
properties and the more successful that candidate is likely to be in preclinical and 
clinical development stages.  It is the investigation into some of these drug-like 
properties of the cyclic prodrugs of DADLE that is the main focus of this chapter.  
Many of the physicochemical properties (e.g., charge, size, hydrogen bonding 
potential) of cyclic prodrugs 2 and 3 have been discussed in the previous chapter.  
The focus will now be on the biologically based drug-like properties (e.g., 
metabolism, intestinal mucosal cell permeation, association with cellular transporters) 
of the cyclic prodrugs.   
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One way to improve the biopharmaceutical properties of a molecule is the 
creation of a prodrug.  We took this prodrug approach in order to improve the 
membrane permeability of the opioid peptide DADLE.  By making cyclic prodrugs of 
DADLE, we have been able to design uncharged molecules that were shown to have 
increased lipophilicity, decreased hydrogen-bonding potential, and unique solution 
structures.6-8  While possessing these favorable physiochemical properties would 
presumably lead to increased transcellular permeability, the cyclic prodrugs have 
been found instead to exhibit low cell membrane permeability.9,10  It has been 
discovered that the cyclic prodrugs exhibit substrate specificity for P-glycoprotein (P-
gp), which results in a significant decrease in cellular permeability.10-12   
Certain biological attributes (i.e. intestinal mucosal cell permeation, 
metabolism, cellular transporter interactions) are important properties to investigate in 
order to achieve and optimize the oral bioavailability of a drug.  The intestinal 
mucosa is known to contain a significant amount of cytochrome P450-3A 
metabolizing enzymes.11-13  Since the P450-3A4 enzyme is prominent in the intestinal 
mucosa and many P-gp substrates also show substrate specificity toward cytochrome 
P450 enzymes,14-17 the metabolic stability of the cyclic prodrugs becomes suspect.  It 
was shown that with the cyclic prodrug CA-DADLE, this is indeed the case (Chapter 
2).  Using this information, potentially more metabolically stable cyclic prodrugs of 
CA-DADLE (1) have been designed (Figure 4.1).  These CA-DADLE analogs have 
been shown to possess favorable physicochemical properties (Chapter 3) that would 
put them in the medium-to-high “bin” for drug-like property characterization.  The  
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Figure 4.1.  Structures of DADLE and cyclic prodrugs of DADLE 
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biological drug-like properties of CA-[Cha4,D-Leu5]-Enk (2) and CA-[Cha4,D-Ala5]-
Enk (3), however, have yet to be tested.  To further characterize the “drugable” nature 
of these analogs, the metabolic stability and cell permeation characteristics of the 
cyclic prodrugs will be determined in vitro and in vivo.  Studies to identify general 
sites of oxidative metabolism on cyclic prodrugs 2 and 3 will also be undertaken. 
 
 
4.2 MATERIAL AND METHODS 
4.2.1 Materials 
Cyclic prodrugs, CA-DADLE (1), CA-[Cha4,D-Leu5]-Enk (2) and CA-
[Cha4,D-Ala5]-Enk (3) were synthesized in our laboratory following described 
procedures.7  Caco-2 cells were purchased from ATCC (Rockville, MD).  Pooled 
male Sprague-Dawley rat liver microsomes (RLM), pooled male Hartely albino 
guinea pig liver microsomes (GPLM), pooled mixed gender human liver microsomes 
(HLM), and recombinant cytochrome P450-3A4 bacrosomes (hCYP3A4) were 
purchased from Xenotech, LLC (Lenexa, KS).  Dulbecco’s modified Eagle medium 
(DMEM) and Hank’s balanced salt solution (HBSS) were purchased from SAFC 
Biosciences (Lenexa, KS).   Fetal bovine serum (FBS), L-glutamine [200 mM (100 
X)], penicillin-streptomycin solution (10,000 units/mL and 10,000 µg/mL, 
respectively, in 0.85% saline), MEM non-essential amino acids solution [10 mM (100 
X)], and trypsin-EDTA solution (0.25%) were purchased from Invitrogen (Carlsbad, 
CA).  D-[1-14C]-mannitol (specific activity 9.25 GBq/mmol) was purchased from 
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Amersham Biosciences (Uppsala, Sweden).  Polyester Transwells® (0.4 um pore size, 
24 mm diameter) were purchased from Fisher Scientific (Pittsburgh, PA).  Rat-tail 
collagen (type I) was purchased from Collaborative Biomedical Products (Bedford, 
MA).  GF120918 was donated by Dr. Kenneth Brower (GlaxoSmithKline, Research 
Triangle Park, NC).  Phosphate buffered saline solution (10 X), trifluoracetic acid, 
and DADLE were purchased from Sigma-Aldrich (St. Louis, MO).  Solvents (HPLC 
grade) were purchased from Fisher Scientific (Pittsburgh, PA).  All chemicals and 
solvents were used as received.   
 
4.2.2 Metabolite Identification 
Phase I oxidative metabolites of cyclic prodrugs 1-3 were determined in 500 
µL of phosphate buffer (100 mM, pH 7.4) containing 50 µM cyclic peptide prodrug, 5 
mM NADPH, and 300 nM P450 enzyme from RLM, GPLM, HLM, or 20 nM 
hCYP3A4 bacrosomes (hCYP3A4).  The solution was incubated for 60 min at 37°C 
then quenched with a stop solution (100 µL of methanol and 750 µL of acetonitrile). 
The mixture was vortexed to mix and centrifuged at 13,000 × g for 15 min.  The 
supernatant (500 µL) was removed and evaporated to dryness (Centrivap 
concentrator, Labconco, Kansas City, MO).  The sample was reconstituted in 100 µL 
of 25% acetonitrile for analysis. 
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4.2.3 In Vitro Microsomal Stability 
Metabolic stability studies of cyclic prodrugs 1-3 were preformed in 500 µL 
of phosphate buffer solution (100 mM, pH 7.4) containing 2.5 µM of cyclic peptide 
prodrug, 1 mM NADPH, and 300 nM P450 enzyme from RLM, GPLM, HLM, or 20 
nM hCYP3A4.  The solution was incubated for 15 min at 37°C then quenched with a 
stop solution (100 µL of methanol and 750 µL of acetonitrile). The mixture was 
vortexed to mix and centrifuged at 13,000 × g for 15 min.  The supernatant (500 µL) 
was removed and evaporated to dryness (Centrivap concentrator, Labconco).  The 
sample was reconstituted in 100 µL of 25% acetonitrile and analyzed using 
LC/MS/MS.  Side-by-side control experiments were performed to monitor non-
enzyme-mediated degradation.  For the control experiments, methanol (100 µL) was 
added to the buffer/NAPDH/prodrug solution before the addition of hCYP3A4 or 
microsomes.  After the addition of hCYP3A4 or microsomes, the reaction was 
quickly stopped with 750 µL of acetonitrile and processed as stated above.  The 
amount of substrate remaining was calculated by dividing the average substrate peak 
area by the average substrate peak area in the control sample.  Statistics were 
performed with Sigma Stat 3.5 using a one-way ANOVA with a Hohn-Sidik multiple 
comparison.   
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4.2.4 In Vitro Cellular Permeation 
4.2.4.1 Cell Culture 
Caco-2 cells were purchased from American Type Culture Collection 
(Rockville MD).  The cells were cultured as previously described.18  Basically, the 
cells were grown in a controlled atmosphere of 5% CO2 and 95% relative humidity at 
37°C in 150 cm2 culture flasks.  The culture medium consisted of DMEM 
supplemented with 10% heat-inactivated FBS, 1% nonessential amino acids, 100 
µg/mL streptomycin, 100 U/mL penicillin, and 1% L-glutamine.  In 3-5 days, 80% 
confluence was reached, and the cells were detached from the culture flask by partial 
digestion using a trypsin/EDTA solution.  The freshly detached cells were used to 
subculture a new flask or plated on collagen-coated polycarbonate membranes 
(Transwell®, 0.4 µm pore size, 24 mm diameter).  The cells were seeded at 7.9 × 104 
cells/cm2 on 6-well Transwell® filter inserts.  The Caco-2 cells were fed with culture 
medium the day after seeding, then every other day until transport experiments were 
preformed [apical (AP) volume 1.5 mL; basolateral (BL) volume 2.6 mL].  The 
membrane integrity was checked post transport experiment using [14C]-mannitol.  
The apparent permeability coefficients (Papp) of [14C]-mannitol across the cell 
monolayers were typically in the range of 0.1-0.8 × 10-6 cm/sec.  Cells used in these 
experiments were between passages 26-34. 
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4.2.4.2 Transport Experiments 
Bi-directional transport experiments were conducted in our laboratory18 with 
only minor modifications.  Briefly, the transport studies were performed at 37°C in a 
shaking water bath (60 rpm) on 21-28 day-old Caco-2 cell monolayers grown on 
collegen-coated polyester membranes (Transwells®).  Both sides of the cell 
monolayers were washed 3 times with pre-warmed HBSS, pH 7.4.  Drug solutions 
(20 µM final concentration) were added to the donor side and fresh HBSS was placed 
in the receiver compartment (1.5 mL for AP chamber and 2.6 mL for BL chamber).  
During inhibition studies, the cell monolayers were pre-incubated with HBSS 
containing inhibitors [GF120918 (10 µM) or PSC-833 (10 µM)] for 15 min to inhibit 
the activity of efflux transports present in the cell monolayers.   Drug compounds 
were then added to the donor side along with their respective inhibitors.  Aliquots 
(200 µL) were withdrawn from the receiver side at various time intervals up to 90 
min.  Fresh HBSS or HBSS containing inhibitor (200 µL) was replaced in the 
receiver side after sampling.  The samples withdrawn were diluted with 25% 
acetonitrile in water (v/v) and then frozen at -80°C until analysis by LC/MS/MS.  
Apparent permeability coefficients (Papp) of the cyclic peptides were calculated using 
the following equation: 
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Papp = (∆Q/∆t)/(A x C0) 
 
where ∆Q/∆t is the linear appearance rate of mass in the receiver solution, A is the 
cross-sectional area (4.71 cm2), and C0 is the initial peptide concentration in the donor 
compartment at t = 0.   
 
4.2.5 In Situ Rat Intestinal Perfusion 
4.2.5.1 Surgical Procedures and Sample Preparation 
The surgical procedures used in the rat intestinal perfusion experiments have 
been previously described.19  Both perfusate and blood samples were collected 
simultaneously during the study.  The isolated ileum segment was perfused at a flow 
rate of 0.2 mL/min with the perfusate being collected at the outlet.  The perfusate 
consisted of perfusion buffer (57.9 mM NaH2PO4, 79.5 mM Na2SO4, pH 6.5) 
containing cyclic prodrug (20 µM) with or without a P-gp inhibitor (PSC-833, 10 
µM).  Blood samples were collected via a direct cannulation of the mesenteric vein 
that was fed from isolated perfused tissue only.  The perfusate and blood samples 
were collected over 5 min intervals from 30-60 min.  The perfusate samples were 
mixed with acetonitrile (1:3, v/v) containing internal standards.  The internal standard 
used to quantify the linear peptide was [Leu5]-Enk, and quantification of the cyclic 
DADLE prodrugs was performed with cyclic [Leu5]-Enk containing a coumarinic 
acid linker.  The blood samples were collected over an esterase inhibitor (paraoxon, 
0.5 mM) to retard the degradation of the cyclic prodrugs by intestinal esterases.  
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Immediately upon collection of each blood sample, the plasma fraction was isolated 
via centrifugation at 1800 × g for 5 min.  The plasma fraction was then mixed with 
acetonitrile (1:3, v/v) containing internal standards.  After all the plasma samples 
were collected, they were centrifuged at 21,000 × g for 15 min to pellet precipitate 
proteins.  Finally, the supernatants from the plasma samples and the perfusate 
samples were dried using a Centrivap Concentrator (Labconco) and stored at -80°C 
until analysis.  For analysis, the samples were reconstituted in 100 µL of 25 % 
acetonitrile, centrifuged to remove particulates, and analyzed by LC/MS/MS (see 
analytical methods).  Each sample was evaluated for the presence of cyclic prodrug, 
linear drug, and oxidative metabolites.    
 
4.2.5.2 Calculations of PB Values From In Situ Rat Intestinal Perfusion 
Experiments 
The apparent mesenteric permeability coefficients (PB) were determined using 
the following equation: 
PB = (∆MB/∆t)/(2πrl x <C>) 
 
where MB is the cumulative amount of drugs (both cyclic and linear) in the blood 
over time (t), r is the luminal radius of the intestine, l is the length of the perfused 
ileum segment and <C> is the logarithmic mean concentration of the drugs within the 
segment.  <C> was calculated using the following equation: 
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<C> = C0[l-(C1/C0)]/ln(C0/C1) 
 
where C0 is the initial concentration of the drugs being perfused and C1 is the 
concentration of drugs being collected at the outlet of the perfused ileum segment.   
 
4.2.6 Analytical Methods 
High-performance liquid chromatography with tandem mass spectrometry 
detection (LC/MS/MS) was employed using a Quattro Micro triple quadrupole mass 
spectrometer.  Liquid chromatography was conducted using a Waters 2690 HPLC 
system. The separation was preformed on a Vydac C18 column (50 × 1.0 mm i.d., 
300Å).  The cyclic peptide prodrugs were isolated using a gradient from 5% to 95% B 
[solvent A: water with 0.1% formic acid (v/v) and solvent B: acetronitrile with 0.1% 
formic acid (v/v)].  The total run time was 20 min with a flow rate of 0.2 mL/min (3 
min gradient from 5% to 40% B; 3 min gradient from 40% to 95% B; 2 min at 95%; 2 
min return to 5% B; 10 min equilibration at 5% B).  The eluate was analyzed by 
electrospray ionization (ESI) in positive mode.  Multiple reaction monitoring (MRM) 
scans were used to determine the presence of the cyclic prodrug parent and the linear 
peptide using the following m/z transitions: parent > 136.0 with parent m/z set at: 
698.4 {CA-DADLE (1)}, 704.2 {CA-[Cha4,D-Leu5]-Enk (2)}, and 662.6 {CA-
[Cha4,D-Ala5]-Enk (3) }.  The oxidative metabolites were identified with the 
following m/z transitions: parent > 102.0, 136.0, 152.0, and 223.0 with parent m/z set 
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at: 714.4 (CA-DADLE + OH), 720.3 (CA-[Cha4,D-Leu5]-Enk +OH), and 678.6 (CA-
[Cha4,D-Ala5]-Enk +OH). 
 
 
4.3 RESULTS 
4.3.1 Metabolite Identification 
Metabolites arising from phase I oxidation of CA-DADLE (1), CA-[Cha4,D-Leu5]-
Enk (2) and CA-[Cha4,D-Ala5]-Enk (3) are seen in Table 4.1.  The data show CA-
DADLE (1) to be hydroxylated at the Tyr1 and Phe4 positions in the presence RLM, 
but CA-DADLE analogs (2 and 3) show oxidation at only the Tyr1 position.  GPLM 
give similar results for CA-DADLE (1), showing hydroxylation at Tyr1 and Phe4.  
CA-[Cha4,D-Leu5]-Enk (2) mirrors this pattern showing hydroxylation on Tyr1 and 
Cha4.  But hydroxylated Tyr1 is the only metabolite formed from CA-[Cha4,D-Ala5]-
Enk (3) in the presence of GPLM.  HLM exhibited the same metabolite formation as 
with GPLM for cyclic prodrug analogs 2 and 3 showing hydroxylation at Tyr1 and 
Cha4 for CA-[Cha4,D-Leu5]-Enk (2), and Tyr1 for CA-[Cha4,D-Ala5]-Enk (3).  CA-
DADLE (1), however, only shows hydroxylation at Tyr1 in the presence of HLM.  
Interestingly, in the presence of hCYP3A4, CA-DADLE (1) shows oxidation at the 
Phe4 position while cyclic prodrug analogs 2 and 3 show no significant metabolite 
formation under the same conditions (Table 4.1).   
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Table 4.1. Metabolites arising from phase I oxidation of CA-DADLE, CA-[Cha4,D-
Leu5]-Enk and CA-[Cha4,D-Ala5]-Enk.  
 
 
Compound RLM 
oxidation 
GPLM 
oxidation 
HLM 
oxidation 
hCYP3A4 
oxidation 
 
CA-DADLE 
 
Tyr1, Phe4 
 
Tyr1,Phe4 
 
Tyr1 
 
Phe4 
CA-[Cha4,D-Leu5]-Enk Tyr1 Tyr1, Cha4 Tyr1, Cha4 No significant 
metabolites 
CA-[Cha4,D-Ala5]-Enk Tyr1 Tyr1 Tyr1 No significant 
metabolites 
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4.3.2 In Vitro Microsomal Stability 
The metabolic stability of DADLE and cyclic prodrugs of DADLE was 
investigated in the presence of RLM, GPLM, HLM, and hCYP3A4 with and without 
inhibitors.  Paraoxon, an esterase B inhibitor, and ketoconazole, a cytochrome P 450 
inhibitor, were the two inhibitors used in the liver microsomal assays. In the presence 
of hCYP3A, only ketoconazole was used since this metabolic stability assay contains 
only P450 enzymes.  As seen in Figure 4.2, DADLE shows 100% parent compound 
remaining in the presence of RLM with and without inhibitors.  The cyclic DADLE 
prodrugs 1-3, however, show a significant decrease in metabolic stability.  In the 
presence of RLM in the absence of inhibitors, CA-DADLE (1), CA-[Cha4,D-Leu5]-
Enk (2), and CA-[Cha4,D- Ala5]-Enk (3) show only 20%, 48%, and 17% of cyclic 
parent remaining, respectively (Figure 2).  Paraoxon did little to improve the 
metabolic stability of the compounds with only 27% of the cyclic parent remaining 
for CA-DADLE (1), 60% for CA-[Cha4,D-Leu5]-Enk (2) and 27% for CA-[Cha4,D-
Ala5]-Enk (3) (Figure 2).  The addition of ketoconazole brought about a significant 
increase in metabolic stability.  The data showed 89% of the cyclic parent remaining 
for cyclic prodrugs 1-2 and 100% remaining for cyclic prodrug 3 (Figure 4.2). The 
combination of inhibitors produced greater than 90% of the cyclic prodrugs being 
detected after a 15-min incubation.   
In the presence of GPLM, the studies indicate that DADLE has 90% of the 
parent compound remaining at 15 min with and without inhibitors (Figure 4.3).  
Cyclic prodrugs 1-3, however, show a significantly decreased amount of cyclic parent  
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Figure 4.2.  Stability of DADLE and the cyclic prodrugs CA-DADLE (1), CA-
[Cha4,D-Leu5]-Enk (2), and CA-[Cha4,D-Ala5]-Enk (3) in the presence of rat liver 
microsomes with and without inhibitors after 15 min incubation.  (*P<0.001) 
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Figure 4.3.  Stability of DADLE and the cyclic prodrugs CA-DADLE (1), CA-
[Cha4,D-Leu5]-Enk (2), and CA-[Cha4,D-Ala5]-Enk (3) in the presence of guinea pig 
liver microsomes with and without inhibitors after 15 min incubation.  (*P<0.001 and 
#P<0.003) 
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Figure 4.4.  Stability of DADLE and the cyclic prodrugs CA-DADLE (1), CA-
[Cha4,D-Leu5]-Enk (2), and CA-[Cha4,D-Ala5]-Enk (3) in the presence of human 
liver microsomes with and without inhibitors after 15 min incubation.  (*P=0.022 and 
#P<0.001) 
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remaining in the absence of inhibitors.  This is illustrated in Figure 4.3 where CA-
DADLE (1) shows 6% of cyclic parent remaining, CA-[Cha4,D-Leu5]-Enk (2) has 
34% remaining and CA-[Cha4,D-Ala5]-Enk (3) shows only 8% remaining.  The 
presence of paraoxon did little to enhance the metabolic stability of cyclic prodrugs 
CA-DADLE (1), CA-[Cha4,D-Leu5]-Enk (2), and CA-[Cha4,D-Ala5]-Enk (3), with 
only 11%, 42%, and 11% of cyclic parent remaining, respectively.  The metabolic 
stability of cyclic prodrugs 1-3 dramatically increases with the addition of 
ketoconazole to over 70% cyclic parent remaining for the CA-DADLE analogs (2 and 
3) to 44% for CA-DADLE (1).  The results from the ketoconazole/paraoxon cocktail 
again mirror the results from ketoconazole alone, showing about 65% cyclic parent 
remaining for all three cyclic prodrugs (1-3).   
In the HLM assays, DADLE again shows a significant amount (94%) of 
parent drug remaining under all conditions (Figure 4.4).  With no inhibitors present, 
15%, 50%, and 20% of CA-DADLE (1), CA-[Cha4,D-Leu5]-Enk (2), and CA-
[Cha4,D-Ala5]-Enk (3) remain (Figure 4.4).  The low recovery of cyclic prodrugs 1-3 
is reversed with the addition of ketoconazole to above 80% in all cases, but remains 
low with the addition of paraoxon alone, showing under 20% of parent drug 
remaining for CA-DADLE (1) and CA-[Cha4,D-Ala5]-Enk (3) and 44% for CA-
[Cha4,D-Leu5]-Enk (2).  A combination of both inhibitors resulted in over 90% of 
cyclic prodrugs 1-3 being detected.   
Cyclic prodrugs 1-3 show significantly different metabolic stability profiles in 
the recombinant hCYP3A4 assays (Figure 4.5).  DADLE shows high stability in the  
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Figure 4.5.  Stability of DADLE and the cyclic prodrugs CA-DADLE (1), CA-
[Cha4,D-Leu5]-Enk (2), and CA-[Cha4,D-Ala5]-Enk (3) in the presence of hCYP3A4 
with and without ketoconazole after 15 min incubation.  (*P<0.001) 
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presence of hCYP3A4 with 98% of parent remaining with and without inhibitors.  
CA-DADLE (1) did not show high stability in the presence of hCYP3A4 in the 
absence of inhibitors, with only 9% of the parent drug remaining under this condition.  
CA-DADLE analogs 2 and 3, however, did display relatively high metabolic stability 
in the presence of hCYP3A4.  The data show 78% of the cyclic parent remaining for 
CA-[Cha4,D-Leu5]-Enk (2) and 87% remaining for CA-[Cha4,D-Ala5]-Enk (3).  The 
addition of ketoconazole did improve the metabolic stability of CA-DADLE (1) five-
fold, but had relatively little effect on CA-DADLE analogs 2 and 3.   
 
4.3.3 In Vitro Cellular Permeation 
The in vitro cell permeability of the cyclic DADLE prodrugs was investigated in a 
Caco-2 cell culture model in the presence and absence of inhibitors (Table 4.2-4.4).  
CA-DADLE (1) shows an apparent permeability coefficient (Papp) ratio of 20.8 
without inhibitors present.  This is significantly reduced in the presence of P-gp 
inhibitors where a Papp ratio of 4.8 is seen in the presence of GF120918 and 3.2 with 
PSC-833.  In the absence of inhibitors, the Papp ratios for cyclic analogs 2 and 3 are 
significantly higher than that for CA-DADLE (1).  CA-[Cha4,D-Leu5]-Enk (2) shows 
a Papp ratio of 131 and CA-[Cha4,D-Ala5]-Enk (3) shows a Papp ratio of greater than 
500 (Table 4.3, 4.4).  As with CA-DADLE (1), the cyclic prodrugs 2 and 3 exhibit 
lower Papp values in the presence of inhibitors.  CA-[Cha4,D-Leu5]-Enk (2) has a Papp 
ratio of 10.7 in the presence of GF120918 and only 2.2 with PSC-833 (Table 4.3).   
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Table 4.2.  Papp values of CA-DADLE (1) across a Caco-2 cell monolayer in the 
presence and absence of known P-gp inhibitors (10 µM). 
 
 
 Papp × 107 (cm/s) Ratio 
Treatment AP-to-BL BL-to-AP (Papp BL-to-AP/ Papp AP-to-BL) 
- 13.3 ± 2.3 276 ± 89.6 20.80 
GF120918  49.0 ± 5.7 237 ± 22.8 4.84 
PSC-833 23.0 ± 1.0 74.1± 7.2 3.22 
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Table 4.3.  Papp values of CA-[Cha4,D-Leu5]-Enk (2) across a Caco-2 cell monolayer 
in the presence and absence of known P-gp inhibitors (10 µM). 
 
 
 Papp × 107 (cm/s) Ratio 
Compound AP-to-BL BL-to-AP (Papp BL-to-AP/ Papp AP-to-BL) 
- 3.4 ± 0.8 442 ± 4.2 131.01 
GF120918  42.6 ± 2.2 457 ± 29.1 10.74 
PSC-833 74.3 ± 8.4 161 ± 11.9 2.17 
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Table 4.4.  Papp values of CA-[Cha4,D-Ala5]-Enk (3) across a Caco-2 cell monolayer 
in the presence and absence of known P-gp inhibitors (10 µM). 
 
 
 Papp × 107 (cm/s) Ratio 
Compound AP-to-BL BL-to-AP (Papp BL-to-AP/ Papp AP-to-BL) 
- <0.03* 62.2 ± 1.8 >500 
GF120918  21.1 ± 3.5 65.7 ± 10.9 3.12 
PSC-833 31.5 ± 11.5 50.3 ± 11.9 1.60 
*Papp AP-to-BL calculated using lowest detectable limits 
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CA-[Cha4,D-Ala5]-Enk (3) shows Papp ratios of 3.1 and 1.6 in the presence of 
GF120918 and PSC-833, respectively (Table 4.4).  The data demonstrate that without 
inhibitors cyclic prodrugs 1-3 have low Papp ratios, but with the addition of P-gp 
inhibitors, a dramatic increase in Papp ratios is seen.  This indicates that the cyclic 
prodrugs 1-3 are substrates for P-gp.   
 
4.3.4 In Situ Rat Intestinal Perfusion 
The in vivo permeation of CA-DADLE (1) and CA-[Cha4,D-Leu5]-Enk (2) has been 
tested via an in situ rat intestinal perfusion model.  Using the in vitro permeability 
data as a guide, the CA-DADLE analog showing the best in vitro permeation {CA-
[Cha4,D-Leu5]-Enk (2)} and the P-gp inhibitor showing the highest inhibition (PSC-
833) were used in the in vivo studies.  The permeability is reported as apparent 
permeability coefficients (PB) in Table 4.5.  The data show that, in the absence of 
inhibitors, very little of the cyclic prodrug is detected in the blood.  This is seen by PB 
values less than 7 (Table 4.5).  However, in the presence of PSC-833, the PB values 
significantly increase.  CA-DADLE (1) has a PB value of 71.6 ×107 cm/s and CA-
[Cha4,D-Leu5]-Enk (2) is found to have a PB value of 65.2 × 107 cm/s.  Oxidative 
metabolites are not detected in any of the blood samples.  It should be noted that the 
control PB value for CA-[Cha4,D-Leu5]-Enk (2) was obtained from lowest detectable 
limit (LDL) calculations.  These calculations were performed since detection was not 
possible because so little of the cyclic prodrug crossed the intestinal barrier.     
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Table 4.5.  Apparent permeability coefficients of CA-DADLE (1) and CA-[Cha4,D-
Leu5]-Enk (2) on the mesenteric blood (PB) side in the presence and absence of PSC-
833.a 
 
 
 PB × 107 (cm/s) 
Compound Control PSC-833c 
CA-DADLE 2.5 ± 0.92 71.6 ± 32.2 
CA-[Cha4,D-Leu5]-Enk  6.5 ± 4.5b 65.2 ± 35.7 
 
 
a. The rat ileum was perfused with 20 µM of each compound in the presence of     
10 µM PSC-833.  The mesenteric blood was sampled after steady-state at 5-
min intervals for 30 min.  The blood samples were extracted and analyzed 
using LC/MS/MS as described in Methods.  Results presented as mean (± 
SEM) with    n = 3-5.   
b. The PB values were estimated from the lowest detectable limits of the 
compound.   
c. PB values for the cyclic prodrugs were based on a sum of prodrug and linear 
compound present in the blood.   
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4.4 DISCUSSION 
The biopharmaceutical properties of CA-DADLE (1), CA-[Cha4,D-Leu5]-Enk (2), 
and CA-[Cha4,D-Ala5]-Enk (3) have been investigated to characterize the drug-like 
properties of these molecules.  Metabolic stability, oxidative metabolite identification, 
and cellular permeation were determined for the cyclic prodrugs 1-3.  Metabolic  
stability assays and metabolite identification have been performed in the presence of 
liver microsomes (RLM, GPLM and HLM) and human recombinant 3A4 bacrosomes 
(hCYP3A4).  Under all conditions studied, DADLE was found to be metabolically 
stable (Figures 4.2-4.5).  Cyclic prodrugs 1-3, however, were found to be 
metabolically instable under many of the same conditions.  In the presence of liver 
microsomes, less then 20% of CA-DADLE (1) and CA-[Cha4,D-Ala5]-Enk (3) remain 
in the absence of inhibitors (Figures 2-4).  For CA-[Cha4,D-Leu5]-Enk (2), the 
amount of cyclic prodrug remaining after 15-min incubation was slightly higher at 
48%.  This shows a slight increase in stability for CA-[Cha4,D-Leu5]-Enk (2) 
compared to the other prodrugs in the presence of liver microsomes (Figure 4.2-4.4).  
The instability of cyclic prodrugs 1-3 in the tested biological media was found to be 
related to cytochrome P450 metabolism.  The data show a significant increase in the 
amount of cyclic parent recovered with the addition of ketoconazole, a cytochrome 
P450 inhibitor.  For CA-DADLE (1) and CA-[Cha4,D-Ala5]-Enk (3), the addition of 
ketoconazole leads to a four-fold increase in stability.  For CA-[Cha4,D-Leu5]-Enk 
(2), the results are less dramatic showing only a two-fold increase.  This suggests that 
CA-[Cha4,D-Leu5]-Enk (2) is slightly more stable toward cytochrome P450 oxidative 
 131
metabolism than the other prodrugs.  While addition of ketoconazole results in a 
significant increase in the amount of cyclic prodrugs recovered, the addition of 
paraoxon, an esterase B inhibitor, only marginally increases the amount of cyclic 
parent recovered in the stability assays (Figures 4.2-4.4).  This suggests that the 
metabolic instability of cyclic prodrugs 1-3 is not likely due to a premature 
bioconversion of the ester prodrugs.   
The metabolic stability assays in the presence of hCYP3A4 show entirely 
different results than those from the metabolic stability studies with liver microsomes. 
CA-DADLE (1) is found to be metabolically unstable in the presence of hCYP3A4, 
but the CA-DADLE analogs 2 and 3 are found to be stable under the same conditions 
(Figure 4.5).  CA-[Cha4,D-Leu5]-Enk (2) and CA-[Cha4,D-Ala5]-Enk (3) both show 
greater then 75% cyclic parent recovered in the presence of hCYP3A4 without 
inhibitors compared to 9% for CA-DADLE (1) (Figure 4.5).  With the addition of 
ketoconazole, this number climbs to 95% for cyclic prodrugs 2 and 3.  This indicates 
that, while CA-[Cha4,D-Leu5]-Enk (2) and CA-[Cha4,D-Ala5]-Enk (3) are 
metabolized to a small extent by CYP3A4, there are probably other isozymes of 
cytochrome P450 that are involved in the metabolism of these prodrugs.   
Metabolite identification studies have been performed to identify the areas of 
metabolic instability in the cyclic prodrugs.  Since opioid activity of the cyclic 
prodrugs has been shown to rely highly on an unmodified tyrosine remaining in the 
first position of the opioid peptide,20-23 this position was chosen to remain unaltered in 
the CA-DADLE analog design.  Unfortunately, oxidation at the Tyr1 position forms a 
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majority of the metabolites for all three cyclic prodrugs (Table 4.1).  Cyclic prodrug 3 
does show less metabolite formation than CA-DADLE (1) in the presence of liver 
microsomes, but it does not show increased metabolic stability in the liver 
microsomal assays compared to CA-DADLE (1) (Figure 4.2-4.4).  The reason for this 
could be that enhancing the metabolic stability of position four in CA-[Cha4,D-Ala5]-
Enk (3) makes Tyr1 more susceptible to hydroxylation in the presence of liver 
microsomes.       
The metabolite identification results are again very different in the presence of 
hCYP3A4 than in the liver microsomal assays.  After a 60-min incubation with 
hCYP3A4, CA-DADLE (1) shows hydroxylation at Tyr1 while the cyclic prodrugs 2 
and 3 show no significant metabolite formation (Table 4.1).  This is consistent with 
the metabolic stability results, which show cyclic prodrugs 2 and 3 to have greatly 
enhanced metabolic stability in the presence of hCYP3A4 (Figure 4.5).  Since 
CYP3A4 is an important barrier to intestinal absorption, proving that CA-[Cha4,D-
Leu5]-Enk (2) and CA-[Cha4,D-Ala5]-Enk (3) are metabolically stable and show no 
metabolite formation in the presence of hCYP3A4 is a significant result.  The 
increased metabolic stability of the chemically modified prodrugs 2 and 3 in the 
presence of hCYP3A4 makes them good candidates for evaluation of their absorption 
after oral administration.  
The in vitro cell membrane permeation of the cyclic prodrugs was tested using 
Caco-2 cell monolayers, a model for the human intestinal mucosa barrier.  These 
results are reported in Tables 4.2-4.4.  The apparent permeability coefficient (Papp) 
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ratios cyclic prodrugs 1-3 in the absence of inhibitors are relatively high.  In each 
case, the intrinsic permeability (AP-to-BL) is quite low compared to the BL-to AP 
values.  This indicates that the cyclic prodrugs are not penetrating the cell membrane, 
and their low permeation is most likely due to apically localized efflux transporters.  
Confirmation of this is seen with the addition of P-gp inhibitors GF120918 and PSC-
833.  In the presence of P-gp inhibitors, the intrinsic permeability dramatically 
increases for all the cyclic prodrugs (Tables 4.2-4.4).  The data show that the cyclic 
CA-DADLE analogs created to solve the metabolism issue are still substrates for     
P-gp.  They are, in fact, even better P-gp substrates than the parent CA-DADLE (1).  
Due to the remarkably low intrinsic permeability of cyclic prodrug 3, cyclic prodrug 2 
has been chosen for in vivo permeability experiments.  Since PSC-833 is the best     
P-gp inhibitor for cyclic prodrug 2, it has also been chosen for the in vivo 
permeability experiments.   
Cyclic analog CA-[Cha4,D-Leu5]-Enk (2) and parent CA-DADLE (1) have 
been used in in situ rat intestinal perfusion studies with the aim of testing the in vivo 
membrane permeability.  The in situ rat intestinal perfusion model allows the 
membrane permeability of the cyclic prodrugs to be tested while simultaneously 
looking for oxidative metabolites.  Since the cyclic prodrugs are known substrates for 
P-gp, inhibitor studies using PSC-833 were performed.  The control experiments 
(cyclic prodrug alone) showed very little membrane permeation by cyclic prodrugs 1 
and 2 (Table 4.5).  However, with the addition of a P-gp inhibitor, the apparent 
permeability coefficient values (PB) showed a 28-fold increase for CA-DADLE (1) 
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and a 10-fold increase in permeation for CA-[Cha4,D-Leu5]-Enk (2) (Table 4.5).  The 
large increase in permeation for both cyclic prodrugs 1-2 in the presence of a P-gp 
inhibitor illustrates that these compounds are substrates for efflux transporters in vivo.  
No metabolites of the cyclic prodrugs were found to permeate the rat intestine even in 
the presence of a P-gp inhibitor.   
 
 
4.5 CONCLUSION 
The biopharmaceutical characteristics of cyclic prodrug analogs 2 and 3 were 
evaluated to test the “drugability” of these molecules.  In the presence of liver 
microsomes, cyclic prodrug analogs 2 and 3 did not show significant increases in 
metabolic stability compared to CA-DADLE (1).  It was found that these compounds 
are metabolized by cytochrome P450 enzymes.  In the presence of hCYP3A4, 
however, cyclic prodrug analogs 2 and 3 were found to have increased oxidative 
metabolic stability compared to CA-DADLE (1).  The improved metabolic stability 
towards hCYP3A4 is important for oral drug delivery since CYP3A4 is the main 
metabolic barrier to intestinal absorption.  Unfortunately, cyclic prodrug analogs 2 
and 3 were found to exhibit poor in vitro permeation.  This is contrary to what was 
anticipated.  Based on the structural and physiochemical properties (i.e., unique 
solution structure, reduced intramolecular hydrogen bonding, increased lipophilicity, 
and decreased charge), the cyclic prodrugs were expected to have good permeation.  
However, the permeation data showed both CA-[Cha4,D-Leu5]-Enk (2) and CA-
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[Cha4,D-Ala5]-Enk (3) to be substrates of P-gp.  In fact, cyclic prodrugs 2 and 3 were 
found to be even better substrates for P-gp than the parent CA-DADLE (1).  The in 
vivo results support the in vitro results showing that P-gp is a major barrier to 
intestinal absorption in vivo.  Increasing the CYP3A4 metabolic stability of cyclic 
prodrug analogs 2 and 3 by amino acid modification did not translate into decreased 
P-gp substrate specificity as hoped.  The overlap in structure-activity relationships 
between cytochrome P450 substrates and P-gp substrates does not hold true in this 
case.  Regrettably, these studies indicated that, in order to improve the oral 
bioavailablity of the cyclic prodrugs, their affinity for P-gp and oxidative metabolic 
stability in the liver would need to be addressed.   
 
 
 
 
 
 
 
 
 
 
 
 
 136
4.6 REFERENCES 
1. Caldwell GW, Ritchie DM, Masucci JA, Hageman W, Yan Z 2001. The new 
pre-preclinical paradigm: Compound optimization in early and late phase drug 
discovery. Curr Top Med Chem  1:353-366. 
2. Lesko LJ, Rowland M, Peck CC, Blaschke TF 2000. Optimizing the science 
of drug development: Opportunities for better candidate selection and accelerated 
evaluation in humans. Pharm Res  17:1335-1344. 
3. Varma MVS, Khandavilli S, Ashokraj Y, Jain A, Dhanikula A, Sood A, 
Thomas NS, Pillai O, Sharma P, Gandhi R, Agrawal S, Nair V, Panchagnula R 2004. 
Biopharmacetuic classification system: A scientific framework for pharmacokinetic 
optimization in drug research. Curr Drug Metab  5:375-388. 
4. Panchagnula R, Thomas NS 2000. Biopharmaceutics and pharmacokinetics in 
drug research. Int J Pharm  201:131-150. 
5. Borchardt RT. 217th ACS National Meeting, Anaheim, CA, 1999. 
6. Bak A, Gudmundsson OS, Gangwar S, Friis GJ, Siahaan TJ, Borchardt RT 
1999. Synthesis and evaluation of the physicochemical properties of esterase sensitive 
cyclic prodrugs of opioid peptides using an (acyloxy)alkoxy linker. J Pept Res  
53:393-402. 
7. Ouyang H, Borchardt RT, Siahaan TJ, Vander Velde DG 2002. Synthesis and 
conformational analysis of a coumarinic acid-based cyclic prodrug of an opioid 
peptide with modified sensitivity to esterase-catalyzed bioconversion. J Pept Res  
59:183-195. 
 137
8. Wang B, Nimkar K, Wang W, Zhang H, Shan D, Gudmundsson O, Gangwar 
S, Siahaan T, Borchardt RT 1999. Synthesis and evaluation of the physicochemical 
properties of esterase sensitive cyclic prodrugs of opioid peptides using coumarinic 
acid and phenylpropionic acid linkers. J Pept Res  53:370-382. 
9. Bak A, Gudmundsson OS, Friis GJ, Siahaan TJ, Borchardt RT 1999. 
Acyloxyalkoxy-based cyclic prodrugs of opioid peptides: Evaluation of the chemical 
and enzymatic stability as well as their transport properties across Caco-2 cell 
monolayers. Pharm Res  16:24-29. 
10. Ouyang H, Tang F, Siahaan TJ, Borchardt RT 2002. A modified coumarinic 
acid-based cyclic prodrug of an opioid peptide: Its enzymatic and chemical stability 
and cell permeation characteristics. Pharm Res  19:794-801. 
11. Ding X, Kaminsky LS 2003. Human extrahepatic cytochromes P450: 
Function in xenobiotic metabolism and tissue-selective chemical toxicity in the 
respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol  43:149-173. 
12. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC 2006. 
The human intestinal cytochrome P450 "PIE". Drug Metab Dispos  34:880-886. 
13. Suzuki H, Sugiyama Y 2000. Role of metabolic enzymes and efflux 
transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci  
12:3-12. 
14. Patel J, Mitra AK 2001. Strategies to overcome simultaneous P-glycoprotein-
mediated efflux and CYP3A4-mediated metabolism of drugs. Pharmacogenomics  
2:401-415. 
 138
15. Wacher VJ, Silverman JA, Zhang Y, Benet LZ 1998. Role of P-glycoprotein 
and cytochrome P450-3A in limiting oral absorption of peptides and 
peptidomimetics. J Pharm Sci  87:1322-1330. 
16. Wang E-j, Lew K, Barecki M, Casciano CN, Clement RP, Johnson WW 2001. 
Quantitative distrinctions of active molecular recognition by P-glycoprotein and 
cytochrome P450 3A4. Chem Res Toxicol  14:1596-1603. 
17. Zhang Y, Guo Z, Lin ET, Benet LZ 1998. Overlapping substrate specificties 
of cytochrome P450-3A and P-glycoprotein for a novel cysteine protease inhibitior. 
Drug Metab Dispos  26:360-366. 
18. Gao J, Hugger ED, Beck-Westermeyer MS, Borchardt RT. 2000. Protocols in 
the application of Caco-2 cells in measuring permeability coefficient of drugs.  
Current Protocols in Pharmacology, ed., New York: John Wiley and Sons. p 1-23. 
19. Ouyang H, Chen W, Anderson TE, Steffansen B, Borchardt RT 2008. Factors 
that restrict the cell permation of cyclic prodrugs of an opioid peptide (DADLE): (I) 
The role of efflux transporters in the intestinal mucosa. J Pharm Sci: Submitted 
20. Hruby VJ, Gehring C 1989. Recent developments in the design of receptor 
specific opioid peptides. Med Res Rev  9:343-401. 
21. Lazarus LH, Salvadori S, Balboni G, Tomatis R, Wilson WE 1992. 
Stereospecificity of amino acid side chains in deltorphin defines binding to opioid 
receptors. J Med Chem  35:1222-1227. 
 139
22. Morgan BA, Smith CFC, Waterfield AA, Hughes J, Kosterlitz HW 1976. 
Structure-activity relationships of methioine-enkephalin. J Pharm Pharmacol  28:660-
661. 
23. Schmidt R, Menard D, Mrestani-Klaus C, Chung NN, Lemieux C, Schiller 
PW 1997. Structural modifications of the N-termial tetrapeptide segment of [D-Ala2]-
deltorphin I: Effects on opioid receptor affinities and activities in vitro and on 
antinociceptive potency. Peptides 18:1615-1621. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 140
 
 
 
 
 
 
 
 
 
Chapter 5 
 
Conclusions 
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The main goal of this dissertation research was to investigate and potentially 
to improve the biopharmaceutical properties of cyclic prodrugs of the opioid peptide 
DADLE.  The cyclic peptide prodrug CA-DADLE (DADLE cyclized with a 
coumarinic acid linker) was used as a model for the development of new cyclic 
prodrugs.  Initially, it was found that incorporation of the peptide into a cyclic 
prodrug caused the peptide to become metabolically unstable.  Investigations into the 
metabolism and metabolite formation led to the discovery that the metabolic 
instability resulted from cytochrome P450 metabolism.  The major metabolites 
formed from CA-DADLE were found to be hydroxylated on the Tyr1 and Phe4 
residues of the peptide.  Using this information, an attempt was made to design cyclic 
prodrugs that would be more metabolically stable.  The amino acid sequence of the 
peptide was modified, creating two new CA-DADLE cyclic prodrug analogs, CA-
[Cha4, D-Leu5]-Enk and CA-[Cha4, D-Ala5]-Enk.     
Metabolite identification and metabolic stability studies of the new cyclic 
prodrugs were explored using liver microsomes and hCYP3A4.  In the presence of 
liver microsomes, the cyclic prodrug analogs were found to form oxidative 
metabolites similar to the metabolites of CA-DADLE, and were found to be 
metabolically unstable in the absence of cytochrome P450 inhibitors.  The 
recombinant human cytochrome P450-3A4 (hCYP3A4) results, however, showed that 
the cyclic prodrug analogs have high metabolic stability and no metabolite formation 
in the presence of hCYP3A4.  This was a vast improvement over CA-DADLE, which 
exhibited metabolic instability and metabolite formation under the same conditions.   
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Physicochemical properties and solution conformations were determined to 
further characterize the two new cyclic prodrugs.  2D-NMR studies and MD 
simulations showed that these cyclic prodrugs posed a unique solution conformation 
containing a type I β-turn.  This defined secondary structure provided evidence of a 
decreased hydrogen-bonding potential for the cyclic prodrugs in comparison to 
DADLE.  Determination of the molecular surface area and cLogP calculations 
demonstrated that the two CA-DADLE analogs were uncharged and more lipophilic 
than linear DADLE.  Overall, these studies illustrated that the cyclic CA-DADLE 
analogs have favorable physicochemical properties, making them good drug 
candidates.     
The favorable physicochemical properties and enhanced cytochrome P450-
3A4 metabolic stability, however, did not lead to increased cell membrane 
permeation.  In vitro cell culture studies showed that the cyclic prodrugs were 
substrates for apically polarized efflux transporters.  Specifically, P-glycoprotein    
(P-gP) was found to significantly limit the cell membrane permeation of the cyclic 
prodrugs.  Analysis of the in vivo cell membrane permeability was performed using 
an in situ rat intestinal perfusion model.  This model was utilized to further 
characterize the cell membrane permeability in vivo as well as to identify permeable 
metabolites.  As expected, the in vivo experimental results reinforced the in vitro 
results, confirming poor intestinal permeability in vivo.  There were no oxidative 
metabolites detected in these studies.  The overall results suggest that in order for the 
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cyclic prodrugs to be viable oral drugs, they must have increased oxidative metabolic 
stability, especially in the liver, and greatly enhanced membrane permeation.   
The poor metabolic stability of the cyclic prodrugs could be addressed in two 
ways: (i) identification of the specific cytochrome P450 enzyme responsible for the 
oxidative metabolism and/or (ii) modification of the peptide to give greater metabolic 
stability.  A further understanding of the cytochrome P450 metabolism in the cyclic 
prodrugs would be valuable.  It was discovered that the cyclic prodrugs were 
metabolically unstable in the presence of rat liver microsomes and guinea pig liver 
microsomes but showed no metabolite formation and high metabolic stability in the 
presence of hCYP3A4.  Interestingly, they did not show increased metabolic stability 
in the presence of human liver microsomes.  This led to the conclusion that other 
P450 isozymes rather than P450-3A4 are responsible for the majority of the 
metabolism of the cyclic prodrug analogs.  It would be of interest to use other 
recombinant cytochrome P450 isolates to identify the particular isozyme that leads to 
this metabolic instability.   
Additional changes to the amino acid sequence of the peptide could also be 
considered to increase metabolic stability.  In designing the cyclic prodrug analogs, 
the tyrosine residue was not modified since it is thought to be necessary for opioid 
receptor recognition.  Unfortunately, it was found that a majority of the metabolites 
identified were related to the Tyr1 residue.  To truly eliminate the cytochrome P450 
metabolism, further modification of the peptide sequence would be needed.  
Discounting the synthetic rigor, future studies could include modification of the Tyr1 
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residue with an amino acid mimic.  Recent opioid peptide research suggests that 
replacing the tyrosine residue with certain tyrosine-like molecules can lead to active 
opioid peptides.1-3  When modifying the tyrosine residue, however, care must be 
taken to maintain opioid receptor affinity.   
Besides the cytochrome P450 metabolism, enhancing the membrane 
permeability of the cyclic prodrugs was a concern with the new cyclic prodrug 
analogs.  The issues of P-gp substrate specificity and membrane permeability, 
however, are complex.  One solution might be to pre-administer and/or co-administer 
a P-gp inhibitor with the cyclic prodrugs.  While not ideal from a clinical perspective, 
we have found that this strategy does significantly increase the bioavailability of the 
cyclic prodrugs in rats.4  Another possible change would be to alter the solution 
conformation of the compounds by increase the ring size of the cyclic prodrugs.  
Addition of amino acids to the peptide backbone or “filler atoms” to the linker would 
form a larger, more mobile structure.  These molecules could possibly have the ability 
to be flexible enough to reach a conformation that would not be recognized as a 
substrate for P-gp and, as cyclic molecules, they would still be lipophilic enough to 
permeate the cell membrane.  In taking this approach, however, size might become an 
issue with cell membrane permeability.  Naturally, when taking this course of action, 
one would  need to consider changes in the physiochemical properties caused by the 
addition as well as the bioconversion of the cyclic prodrug.   
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